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ABSTRACT
TARGETED MAGNETITE TISSUE DELIVERY:
IMPLICATIONS TOWARDS IMPROVING ANTIRETROVIRAL PHARMACOKINETICS
Tianyuzi Li, Ph.D.
University of Nebraska Medical Center, 2015
Supervisor: Howard E Gendelman, M.D.
Pharmacokinetics and pharmacodynamics studies are required for bench to bedside
translation of any new drug, formulation or device. Multifunctional magnetite nanocarriers
enable magnetic resonance imaging tracking of nanomaterial encased antiretroviral
drugs serving to improve the effectiveness of formulation developments. Targeting
ligands used to deliver nanoparticles to HIV harboring cells can be tested using
multifunctional magnetite nanocarriers. To this end, two types of magnetite nanocarriers
were developed. These included small magnetite antiretroviral therapy particles. The
second were ALN-PEG coated magnetite particles for testing macrophages targeting
ligands. Overall, these works should serve to speed the development of long acting
nanoformulated ART to improve access and effectiveness of treatment regimens for the
infected human host.
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1.1. The HIV pandemic
The first cases of acquired immunodeficiency syndrome (AIDS) were reported in
1981. Today tens of millions of people have died of AIDS-related causes. At the end of
2013, there are approximately 35 million people currently living with human
immunodeficiency virus (HIV), the virus that causes AIDS. HIV has become one of the
world’s most significant health and development medical challenges. Intensive research
had been done during the past 34 years. Directed collaborative and aggressive efforts on
behalf of scientists and physicians worldwide has increased our knowledge of the HIV
replication cycle, disease pathogenesis, innate and adaptive immunity and antiretroviral
therapy (ART).
In 1987, azidothymidine (AZT) became the first approved HIV treatment. Since then,
approximately 30 drugs were approved for treatment of HIV patients. Nearly a decade
later, major breakthroughs were made with the introduction of a therapy that combined
several drugs to limit the viral resistance and limit HIV replication to very low and often
undetectable levels. Combination ART markedly reduced disease morbidity and mortality
(1, 2). However, ART can only suppress the replication of HIV and does not eliminate it.
Thus, new drugs, delivery systems and vaccines are in desperate need if an HIV cure is
to be achieved.

1.2. HIV virology
HIV is a 100nm retrovirus including two identical copies of single-stranded RNA. It is a
highly organized structure consisting of a cylindrical center surrounded by a
sphere-shaped lipid bilayer where the viral envelope is attached. There are three
structural genes contain the information needed to make structural proteins for new virus
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particles: gag which encodes the structural proteins of the core and matrix, env which
encodes the viral envelope glycoproteins, pol which encodes the viral enzyme (3).
The basic structure of HIV is as follows (Figure 1):
- The viral envelope, outer coat of the virus, consists of two layers of lipids: glycoprotein
(gp) 120 and the transmembrane gp41. Both of the two are encoded by env gene and are
embedded in the viral envelope where "spikes" are formed. The lipid membrane is taken
from the host cell during the budding process.
- The HIV matrix proteins consists of the p17 protein that is encoded by gag gene. They
lie between the envelope and core.
- The viral core contains the viral capsid protein p24 which is encoded by gag gene. The
viral capsid surrounds two single strands of RNA as well as enzymes needed for HIV
replication, including reverse transcriptase, protease, ribonuclease, and integrase. All the
enzymes are encoded by pol gene.
Viral particle membrane is consisting of glycoprotein heterodimer complexes. Gp120
and transmembrane gp41 are the two major elements in the complex. The function of
gp120 and gp41 is to mediate host cell recognition, cell attachment as well as cell
invasion in CD4+ T lymphocytes and monocyte-macrophages (4). Beneath the viral
lipoprotein membrane, is the matrix protein p17, the core proteins p24 and p6, and the
nucleocapsid protein p7 which bound to the RNA. The capsid contains viral genome,
reverse transcriptase, integrase and protease (5).
HIV virus is also characterized by its accessory/regulatory genes which encode
proteins with various regulatory or immuno-modulatory functions (6), including tat
(transactivator of transcription), rev (regulator of viral protein expression), vif (viral
infectivity protein), vpr (viral protein R) and nef (negative regulatory factor). Among them,
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tat protein, which promotes the expression of HIV gene, is expressed very early after
infection. The rev protein ensures the export of the messenger RNA and genomic RNA
from nucleus to cytoplasm. The function of the other accessory HIV proteins is less well
understood.
Previous sequencing studies using samples from HIV infected patients identified that
HIV virus DNA primarily exist in CD4+T lymphocytes, which suggests that CD4+ T cell is
the primary target of HIV infection. Subsequent mechanistic studies revealed the life
cycle of HIV replication in T cells. Before entering cells, the glycoproteins on viral
envelope target and bind to the CD4 receptor on host cells. This interaction triggers a
conformational change of viral glycoproteins and facilitate the interaction of virus and
another two co-receptor on host cells, CCR5 and CXCR4. The interaction with
co-receptors again triggers a conformational change of viral envelope proteins gp41 and
enable virus envelope pierces host cells membrane. Next, virus envelope fuses with host
cell membrane and virus genetic materials and enzymes are injected into host cells, while
the envelope of HIV is left on the membrane of host cells.
The genetics materials of virus was coated by a protective viral capsid, which is
digested in host cells to expose the containing viral RNA as well as key viral enzymes
such as reverse transcriptase. Reverse transcriptase converts viral RNA into a single
strand cDNA by using host deoxynucleotides and this process occurs within a complex
consist of viral capsid and another host cell protein cyclophilin A. The synthesis of viral
DNA occurs together with the degradation of its template RNA, which is mediated by the
RNase activity of viral reverse transcriptase. Notably, this reverse transcription process
leads to random mutation on the newly synthesized single strand DNA due to the poor
proofreading capability of viral reverse transcriptase. These random mutations provide
essential mechanism for virus to evolve and/or gain drug resistance. The single strand
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DNA is later converted into double strand DNA through another round of reverse
transcription. After the double strand DNA is generated, viral integrase binds with this
viral double strand DNA and carries it into the host cell nucleus. Integrases also create a
nick on host chromosome to facilitate the integration of viral DNA into host DNA and gaps
are repaired by host cell DNA repair mechanism. The success of viral DNA integration
marks the completion of HIV infection. Followed by the viral DNA integration,
mechanisms of host cell DNA replication, RNA transcription and protein translation
produce virus genomic materials and viral proteins. They are transported and gathered at
cell membrane for virus packaging. Some viral enzymes can mediate these process. For
example, viral protein Tat can transactivate transcription by binding the 5’ end of the viral
DNA, resulting 1000 time increase of viral transcription (7).
To generate functional virus particle, the HIV DNA firstly produce a pre-protein
encoded by pr55, which will be digested to become functional elements. Similarly,
Gag-Pol is also a pre-protein and can be digested into three functional enzymes:
protease, integrase, and reverse transcriptase. Pre-protein Gp160 migrates to the cell
membrane and is cleaved during the virion formation to form the envelope protein gp41
and gp120. These proteins and host membrane proteins are incorporated on the plasma
membrane to form viral envelope outside the capsid that contains the viral RNA genome.
HIV particles are then assembled and released from host cells (8) (9) (10) (11).

1.3. HIV pathogenesis
There are two types of HIV, HIV type 1 and 2 (HIV-1, 2). There is limited knowledge
about HIV-2, which has not been widely seen outside of Africa. Studies have shown
striking similarities but also significant differences between the two. HIV-2 infection in
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human host is characterized by lower transmission rates, longer asymptomatic stage,
slower decline in numbers of CD4+ T lymphocytes and lower mortality rate (12-15).
HIV-1 transmission occurs through exchange of body fluid from a virus carrier to an
uninfected recipient. Body fluids that can pass HIV-1 virus include blood, semen,
pre-seminal fluid, rectal and vaginal fluids, and breast milk. To transmit HIV, virus
containing body fluids must contact with a mucous membrane or damaged tissue or be
directly injected into the bloodstream.
HIV enters CD4+ cells via its interactions with CD4 receptor and the chemokine
coreceptors, CXCR4 or CCR5. Cells bearing CD4 and chemokine receptors are activated
CD4 T lymphocytes, resting CD4 T cells, monocytes and macrophages, and dendritic
cells.
HIV infect cells mainly through two mechanisms. One is cell-free transmission and the
other one is cell-to-cell transmission. In cell-free transmission, virus floats in plasma and
infects T cells it encounters. In the cell-to-cell transmission, the virus is exchanged by
direct cell contact between infected T cells and uninfected T cell.
In the first 24 hours after infection, HIV infects dendritic cells within the mucous
membranes and skin. Within five days, HIV infects dendritic cells and makes their way to
the lymph nodes as well as peripheral blood where spreading viral replication ensues. In
response to the viral antigen, CD4+ T lymphocytes are then recruited and migrate to
lymph nodes where they become activated and proliferate with the help of
pro-inflammatory cytokines (16). As the consequence, a suitable environment for viral
replication is created (17).
HIV infected cells have a shortened life span as a result of the virus infection (18) and
immune system destruction occurs concomitantly. On the other hand, HIV infected

7

monocytes are more resistant to the toxicity of HIV (19). Thus, monocyte-macrophages
act as reservoirs of HIV and effectors of tissue damage in organs such as the lung and
brain.

1.4. The immune response to HIV
HIV infection leads to abnormality of immune system. Recent studies revealed
immune responses may control HIV infection, although this defensive effect is mostly
transient. These responses include humoral immune response, in which cytokines and
antibodies are produced to prevent HIV infection, and cellular immune response, in which
T cells are activated to enhance their cytotoxicity. Details are shown below.
Cellular immune responses: At the early stage of HIV infection, CD4+ T cells
decrease dramatically while CD8 T cells are activated and expanded up to 20 times
higher. Activated CD4+ T cells promote maturation of CD8+ T cells, which possess
specific and effective anti-HIV toxicity. A number of cytokines are secreted to enhance
this cellular immune responses, such as interleukin-2 and interferon gamma. CD8+ T
cells can also secrete chemokines to block the entry of HIV virus to host cells, such as
CCR5 ligands RANTES (regulated on activation, normal T cell expressed and secreted),
MIP-1 and CXCR4 ligand SDF-1. Notably, a clinical study identified a reverse correlation
between level of these cytokines and HIV disease progression (20).
Humoral responses: The humoral immunity includes B cells and their production of
antibodies. Four to eight weeks after HIV infection, anti-HIV antibodies start to be
generated. These antibodies mainly target viral envelope proteins. Thus cell-free virions
are their main targets, although some antibodies may also destroy HIV-infected cells.
Most antibodies cannot prevent cell to cell transmission of HIV.
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As mentioned above, although immune response provide transient defensive
mechanisms to control HIV infection, HIV may develop strategy to escape from these
defensive immune response, such as antigenic variation (21) (22), decreasing surface
MHC molecules expression as well as depleting CD8+ T cells, etc. (23). Another
limitation of anti-HIV antibody is that virus is able to mutate their envelop protein to evade
attack of antibodies and B-cells are not able to keep up with HIV antigens mutations
speed.
As more CD4 + T cells are eliminated with the infection progress, the CD4 T cell
count keeps dropping. When it reaches below 200 cells/mm3 blood, the patient develop
AIDS (24) (25). To obtain a better picture of disease progression, CD4/CD8 cell ratio
should be monitored which has a normal ratio of about 1 to 1.5. If the disease is
progressing, the CD4/CD8 ratio will be <1, indicating disease progression.

1.5.

Antiretroviral therapy

ART consists of a combination of drugs targeting the human HIV life cycle and act on
different viral life cycle targets. It has led to profound decreases in morbidity and mortality
rates in AIDS patient. It also provides effective treatment to prevent transmission from
male to females and in men who have sex with men (26, 27). Inhibitors of HIV-1 reverse
transcriptase and the viral protease, when used together, cause dramatic reductions in
viremia. For many treated patients, plasma levels of HIV-1 RNA drop to less than the
limits of detection as a result of ART treatment.
ART fall into five classes: 1) nucleoside reverse transcriptase inhibitors (NRTI) and
nucleotide

reverse

transcriptase

inhibitors

(NtRTI),

2)

non-nucleoside

reverse
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transcriptase inhibitors (NNRTIs), 3) protease inhibitors, 4) entry inhibitors and 5)
integrase inhibitors.
Seven nucleoside/nucleotide analogs are Food and Drug Administration (FDA)
approved HIV-1 drugs. NRTIs were the first medicines to be approved for the treatment of
HIV. It stop HIV from replicating within cells by inhibiting the reverse transcriptase. NRTIs
are analogues of the deoxynucleotides needed to synthesize the viral DNA. They
compete with the natural deoxynucleotides for incorporation into the growing viral DNA
chain. Once incorporated, these analogs stop following incorporation of deoxynucleotides
into the DNA chain because of the absence of a 3’ OH group. The next incoming
deoxynucleotide cannot form the next 5’–3’ phosphodiester bond needed to extend the
DNA chain. Thus, when an NRTI or NtRTI is incorporated, viral DNA synthesis is halted
(28).
While only one NtRTI, Tenofovir is currently approved at this time, they act very much
the same way as NRTI (29). Nucleoside analogs are converted into nucleotide by
undergo phosphorylation to become active by the body. Nucleotide analogues bypass
this step, given that they are already chemically activated.
Five NNRTIs are available on the market. The first NNRTIs was approved in 1996. It
stop HIV replicating within cells by interfering with HIV's reverse transcriptase. Unlike
NRTIs, NNRTIs are not incorporated into the viral DNA. Instead it inhibits reverse
transcriptase by binding to an allosteric site of the enzyme (30). Since NNRTI-resistance
mutations can emerge relatively quickly (31) (32), an NNRTI is generally used in
combination with NRTIs.
There are two types of entry inhibitor, Enfuvirtide and Maraviroc. Binding of viral
envelope to its primary receptor CD4 is mediated by gp120, the surface subunit of the
envelope. In its native form, the envelope glycoprotein is a heterotrimer of three gp120
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molecules and three molecules of gp41 (33) (34). Binding to CD4 conformational
changes gp120 and enable its binding to one of two chemokine receptors, CCR5 or
CXCR4. Co-receptor binding allows the fusion peptide of the gp41 to insert into the target
cell membrane, resulting in fusion of virus with the cell membrane (35). Maraviroc works
by targeting CCR5 which located on human helper T-cells. The drug binds to CCR5,
thereby blocking the HIV protein gp120 from associating with the receptor. Enfuvirtide is a
peptide drug which must be injected to give. It acts by interacting with the N-terminal
heptad repeat of gp41 of HIV to form an inactive hetero six-helix bundle, therefore
preventing fusion of the virus with the host membrane (36).
Currently, there are three integrase inhibitors. Integrase facilitates the interaction
between viral DNA and a number of cellular cofactors which is indispensable for
establishing the pre-integration complex (PIC) (37) (38). Upon the formation of the PIC,
integrase remove a nucleotide from viral DNA exposes hydroxyl groups of its 3’ terminal.
Subsequently, PIC enters the host nucleus and creates binding sites on host DNA by
exposing its 5’ phosphate groups. This allows the viral DNA integrates into host DNA,
which is also called strand transfer and is facilitated by integrase, followed by gaps repair
(39). Integrase inhibitors disturb strand transfer process and therefore preventing the viral
DNA from integrating into host DNA.
FDA also approved 8 protease inhibitors. When cells are infected by HIV, they
produce viral proteins for viral packaging. However, newly synthesized viral protein are
not infectious unless they are cleaved by the vial protease. Protease inhibitors target viral
protease and therefore block viral precursor from maturation. Notably, protease inhibitors
are frequently used in combination with other categories of ART drugs to effectively treat
HIV infection.
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ART is now recommended for all adults with HIV infection. Recommended initial
regimens include 2 NRTIs (abacavir/lamivudine (3TC) or tenofovir (TDF) disoproxil
fumarate/emtricitabine (FTC)) and a third single or boosted drug, which should be an
integrase inhibitor (dolutegravir, elvitegravir, or raltegravir), a NNRTIs (efavirenz (EFV) or
rilpivirine) or a boosted protease inhibitor (darunavir or atazanavir) (40).
The World Health Organization (WHO) published the leading recommendations for
antiretroviral treatment in 2013. The favored recommendation is a fixed-dose
combination of TDF; 3TC or FTC and EFV.
It had been shown that the concentration of HIV-1 in plasma drops by impressive
~99% in the first two weeks of ART treatment (41). New drugs with high potency, low
toxicity and tolerability increase the feasibility of early initiated lifelong treatment.
However, even with current ART regimens, HIV is not completely eradicated and
virus is able to remain as a life-long infection due to its ability to stay hidden in restricted
manner within infected blood cells. It is becoming clear that the viral reservoirs present a
major obstacle to clear infection.

1.6. HIV reservoir
Many viruses have established mechanisms to escape from host immune
surveillance through the process of natural selection (42). This persistence always
involves viral reservoirs, on both cellular and anatomical level. In the mid-1990s, a series
of reports showed the existence of provirus within latently infected resting life-long
memory CD4+ T lymphocytes (2, 43) and these virus reservoirs, even after successful
administration of ART, can produce infectious virus following cellular activation (44-46).
Therefore HIV is able to remain a chronic life-long infection due to its ability to stay hidden
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in cellular reservoirs. These reservoir cells contain the genetic code of HIV. Anatomical
reservoirs of HIV are located throughout the body including the brain, lymphoid tissue,
bone marrow, and the genital tract.
In patients receiving ART, latent replication-competent HIV-1 provirus has been
demonstrated in resting memory CD4+ T lymphocytes while low levels of virus can also
be found in resting naïve CD4+ T cells (47). This latent reservoir, drives viral rebound
once ART is stopped. It is established soon after primary HIV-1 infection (48) and can be
activated by pro-inflammatory cytokines (49). The presence of HIV-1 in peripheral blood
monocytes of patients with current ART treatment has also been demonstrated (50).

1.7.

Macrophage viral reservoir

In addition to HIV-1–infected CD4+ T cells, monocyte-macrophages may also be a
key source of the viral reservoir in HIV-1–infected people. Macrophages are referred to
as mononuclear phagocytes (MP) cells derived from circulating monocytes, and are
terminally differentiated, non-dividing cells (51). They can be found in various tissues
using different names (e.g. microglia in the brain, alveolar macrophages in the lung, or
Kupffer cells in the liver) (51). MP are well known to phagocytose cellular debris and
pathogens and act as antigen presenting cells (52). The life spans of the MP vary.
Inflammatory macrophages die after a few days (53), whereas microglia or alveolar
macrophages can live from several weeks up to years. MP are widely distributed in many
different tissues and are able to infiltrate virtually all organs especially the brain, this
make them a critically contributor to the spread of HIV in human body (54, 55).
HIV in infected MP are more resistant to lentiviral replication’s cytopathic effects when
compared with activated CD4+ T lymphocytes (56). Second, HIV has evolved
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sophisticated mechanisms to prolong the life span of infected MP (57, 58). Therefore
long-lived MP may harbor the virus for long period of time, thus constituting HIV
reservoirs and posing a major obstacle to virus eradication from infected individuals.
Mature HIV-1 can be found in intracellular vesicles of MP, suggesting macrophages’
ability to store HIV particles (59). Research showed that MP could store infectious HIV for
weeks (60).
Also, it has been shown that high molecular weight substances, including broadly
neutralizing antibodies are excluded from the virus storing compartments (61, 62). HIV
particles harboring in compartments like exosomes and microvesicles can also be
released to facilitate and increase HIV dissemination (63). This may also contribute to
HIV rapidly transfer from MP internal compartments to adjacent CD4+ T cells and
uninfected monocyte-derived macrophage (MDM) (64, 65). In summary, MP make a
prefect hideout for HIV particles, and growing evidence suggesting an important role of
macrophages in the failure of the immune system to achieve HIV clearance within the
acute and chronic phases of infection (Figure 2). Therefore, targeting delivery ART to
monocytes/macrophages should be a powerful means to eliminate not only HIV but an
opportunity to use the very mechanisms the virus uses to escape destruction. In this
manner depots within MP can be ensured for drug depot and delivery.

1.8.

ART MP delivery schemes

MP are widely distributed in many tissues to recognize and clear altered and
senescent cells, invading particulates, as well as macromolecular ligands via a multitude
of receptors (66). This endocytosis/phagocytosis tendency of MP of foreign particles has
provided an opportunity for the efficient delivery of therapeutic agents to these cells with
the aid of carefully designed colloidal drug delivery systems.
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To further take advantage of this property, nanoparticles have been designed to
maximize macrophages uptake by altering nanoparticles physicochemical properties,
which play a major role in its interaction with serum proteins and MP, as well as adding
targeting ligands to the cell surface. The rate and the site of the uptake of the
nanoparticles by MP are also influenced by the injected dose, blood flow and local tissue
damage (67).
Physicochemical properties of nanoparticle including size, charge, and shape which
can have a very significant effect on the nanoparticles’ efficiency to target MP. In addition
to controlling the physicochemical properties of nanoparticle to facilitate macrophages
targeting, ligands can be incorporated into nanoparticle to specifically target monocytes
and macrophages.
Using a ligand targeting strategy has advantages of potentially increasing target
specificity and avoiding the need for cationic lipids to trigger intracellular delivery.
Successful homing of drugs to the target would help the nanoparticles to preserve its
integrity, avoid interception by normal cells, penetrate interposing membranes, and
reduce the drug dose and potential to diminish the side effects.
In this section we highlight some approaches researchers have used to target MP for
drug delivery and treat HIV disease. Identifying molecular targets within this cell
population will help in creating new therapeutic solutions. A variety of ligands for
macrophage targeting have been studied including peptides, antibodies, proteins,
polysaccharides, glycolipids, glycoproteins, and lectins, which make use of mononuclear
phagocytes characteristic receptor expression and phagocytic innate processes.
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1.8.1. Peptides
Cell targeting peptides and cell penetrating peptides have been used to achieve cell
specific targeting and improve cell uptake. Tuftsin is a natural macrophage activator
tetrapeptide (Thr–Lys–Pro–Arg) which is a part of the Fc-portion of the heavy chain of the
leukophilic immunoglobulin G. This tetrapeptide is released after enzymatic cleavage as
the free peptide fragment (68). Tuftsin is known to not only bind specifically to monocytes,
macrophages and polymorphonuclear leukocytes, but also enhances their natural killer
activity (69). These include potentiation of various cell functions, such as phagocytosis,
pinocytosis, motility, immunogenic response, bactericidal and tumoricidal activities (69).
Conjugating tuftsin onto the nanoparticles can not only homing the drug to macrophages
but also to stimulate these cells non-specifically against infections (70). In one study,
tuftsin were grafted on the surface of the drug-loaded liposomes which were given to
Mycobacterium tuberculosis (MTB) infected animals twice weekly. Rifampin, an anti-MTB
drug delivered for 2 weeks in tuftsin-bearing liposomes was at least 2,000 times more
effective than the free drug in lowering the load of lung bacilli in infected animals (71).
A

short

nicotinic

acetylcholine

receptor

(AchR)-binding

peptide

(YTIWMPENPRPGTPCDIFTNSRGKRASNG) derived from the rabies virus glycoprotein
(RVG) was used to target AchR expressed on macrophage/microglia surface. This
peptide was fused to nona-D-arginine residues (RVG-9dR) to enable siRNA binding (72).
SiRNA bond to RVG-9dR was able to induce gene silencing in wild type macrophages
and microglia, but not in cells from AchR-deficient mice, confirming targeting specificity
(72). Intravenous injection with RVG-9dR-complexed siRNA in mice reduced the
lipopolysaccharide (LPS) induced TNF-α levels in blood as well as in the brain, leading to
a significant reduction in neuronal apoptosis (72). These results demonstrate that
macrophages targeting peptide RVG-9dR provides a platform for siRNA delivery to
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macrophages and across blood brain barrier to microglia and that suppression of TNF-α
can potentially be used to suppress neuroinflammation in vivo.
Arginine-glycine-aspartic acid (RGD)-peptide has also been used to target integrin
receptors expressed by monocytes (73). The interaction between the RGD domain on the
integrin molecule and the integrin receptor on leukocytes stimulates phagocytosis by
polymorphnuclear leukocyte (e.g.neutrophils) (74). In an ex vivo experiment using
negatively charged uncoated and RGD-coated liposomes, amount of drug recovered
from monocytes/neutrophils was 57.8±4.1% and 73.5±5.8% respectively (75). Also,
RGD-coated magnetic liposomes brain levels of the drug was 1.5-fold compared to
uncoated magnetic liposomes and 9.1-fold compared to free drug solution. Results
clearly showed better localization of RGD-coated vesicles within these cells (75).

1.8.2. Mannose
C-type lectin receptors (CLRs) are pattern recognition receptors which are expressed
by macrophages and dendritic cells, with highly conserved carbohydrate-recognition
domains that bind sugar moieties (e.g., mannose, fucose, and glucan) on the surface of
certain pathogens (76). The C-type designation is from their requirement for calcium for
binding. Ligand recognition by CLRs leads to pathogen internalization via receptor
mediated endocytosis. The pathogen is subsequently digested and presented as antigen
to T cells in the context of major histocompatibility complex (MHC) class I or MHC II, or
both. These receptors play numerous roles in immune function including antigenic
recognition, endocytosis, antigen presentation and immune responses.
The mannose receptor (MR) is a 175-kD C-type lectin type I transmembrane protein
(77).

Immune

cells

including

alveolar

macrophages,

peritoneal macrophages,

monocyte-derived dendritic cells, and Kupffer cells constitutively express high levels of
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the MR. Macrophages and DCs can therefore be targeted via mannosylated
nanoparticles which have been shown to preferentially target CLRs on macrophages and
DCs repeatedly, resulting enhanced cellular uptake in vitro and in vivo. Mannosylation
has been achieved by the incorporation of various ligands. A novel mannosylated
cholesterol

derivatives,

cholesten-5-yloxy-N-(4-((1-imino-2-d-thiomannosylethyl)amino)butyl)formamide
(Man-C4-Chol), as a ligand for mannose receptors was studied by several groups (78-80).
Hasida and colleagues tried to deliver dexamethasone palmitate to alveolar
macrophages with selective targeting of mannosylated liposomes via mannose
receptor-mediated endocytosis after intratracheal administration. Dexamethasone
palmitate incorporated in mannosylated liposomes (DPML) was extensively retained in
alveolar macrophages compared with free drug (P < 0.001) and dexamethasone
palmitate containing bare liposomes in LPS induced lung inflammation in rats. The
anti-inflammatory effects of DPML in rats showed significantly inhibited tumor necrosis
factor α, interleukin-1β etc in the lung (78).
4-aminophenyl-α-d-mannopyranoside was conjugate to liposomes to deliver drugs to
alveolar macrophages to study biodistribution (81) or to treat respiratory intracellular
parasitic infections (82). The pulmonary administration and antibacterial activity of
ciprofloxacin-loaded mannosylated liposomes against the intracellular bacteria were
assessed. The antibacterial activity against various intracellular bacteria such as
Chlamydophila pneumonia, Legionella pneumophila, Listeria monocytogenes and
Francisella tularensis as estimated by pharmacokinetic (PK) and pharmacodynamic (PD)
analyses was higher using liposomal systems (82). However, efficacy studies using the
pathogens need to be performed to support the results.
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Other mannose ligands used to target macrophages including alkylmannosides (83),
Mann-His-C4-Chol (84) and Man2DOG (85).

1.8.3. Antibody
Antibody therapy has received wide attention due to its ability to selectively target
cells through receptor-specific interactions (86). Antibody–nanoparticle conjugates have
the potential to elicit effective active targeting and release of therapeutic targets at the
disease site, while minimizing off-target side effects caused by dosing of normal tissues.
Class II human leukocyte antigens (HLA) present antigenic peptides to regulatory T
cells. Follicular dendritic cells (FDC), B lymphocytes, activated CD4+ T-cells and antigen
presenting cells like macrophages are abundant in lymphoid tissues and all express
substantial levels of the HLA-DR. Liposomes bearing surface-attached anti-HLA-DR
antibodies make an interesting approach to target specifically HIV reservoirs as well as
free HIV particles trapped in the FDC network. In one study, the ability of liposomes
bearing anti-HLA-DR fragments at the end termini of PEG chains to target HLA-DR
expressing cells was evaluated. Study showed that anti-HLA-DR bearing liposomes
accumulated better in brachial and cervical lymph nodes than that of conventional
liposomes upon a single subcutaneous injection. In contrast, other organs like liver did
not show especially higher levels when compared to the unmodified liposomes (87).
Growth factors produced by injured endothelial cells induce expression of vascular
cell adhesion molecule-1 (VCAM-1) in monocytes/macrophages. Antiproliferative
cyclopentenone prostaglandins (CP-PGs) are powerful anti-inflammatory agents, with the
help of VCAM-1 antibody, one group developed a negatively charged liposome-based
pharmaceutical formulation (LipoCardium) which direct CP-PGs towards the injured
arterial wall cells of atherosclerotic mice. After 4 months in a high-lipid diet, all low-density
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lipoprotein receptor-deficient control mice died from myocardium infarction or stroke in
less than 2 weeks, whereas LipoCardium-treated mice even though still under high-lipid
diet completely recovered from vascular injuries (88).

1.8.4. Folic acid
A vitamin, folic acid has recently emerged as a prominent targeting moiety capable of
specific interaction with cells expressing the folate receptor (FR). FR consists of a high
affinity (Kd ~ 10-9 - 10-10) folate binding protein attached to the membrane through a
glycosylphosphatidyl-inositol anchor (89). Following binding of folate acid, rapid
endocytosis delivers a fraction of the receptors into the cell (90). Importantly, covalent
conjugation of protein, small molecules or even liposomes to folic acid does not alter its
ability to bind the FR and undergo endocytosis (91); therefore, this makes folate acid a
good targeting ligand to use to help drug enter cells by receptor-mediated endocytosis.
FR expression is restricted to few cell types, including kidney and placenta, while
normal tissues express low or undetectable levels of FR (92). There are three major
forms of the FR, FR-α, FR-β, and FR-γ. The FR-α isoform is present primarily in placenta,
kidney, malignant tumors and various cancer cell lines (89). FR-β is expressed in the
placenta, monocytic and myelocytic lineages of hematopoietic cells and certain
leukemias while there is negligible expression of this molecule on other blood cells such
as lymphocytes, granulocytes, or erythrocytes (89). In contrast, it is difficult to find FR-γ,
which is primarily a secreted isoform of hematopoietic origin under normal conditions
(93).
The feasibility of using FRβ to mediate the specific delivery of molecules is based on
several unique biologic characteristics of the FR. Interestingly, very little folate conjugate
is detected in blood cells or bone marrow after intravenous administration, cause FR-β
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has been found to be functionally inactive although they can be easily detected by
anti-FR-β antibodies (94). Recently, it has been reported that activated but not resting
macrophages, possess a functionally active FR-β, thus FR as a marker of macrophage
activation enables the facile labeling, isolation, and treatment of these inflammatory cells
with folate conjugates (95).
FR has been actively pursued to target nanocarriers to the site of inflammation for
improved delivery and efficacy in arthritis and atherosclerosis (96, 97). In one study FA
conjugated dendrimers was used to target macrophages and deliver methotrexate (MTX)
as an antiinflammatory agent in a collagen-induced arthritis model in rats. The
administration of FA- and MTX-conjugated dendrimer yields significant and beneficial
protection from the inflammatory characteristics of collagen-induced arthritis (96).
Anti-FRβ antibody was also used to target FRβ+ macrophages. A recombinant
immunotoxin consisting of the truncated Pseudomonas exotoxin A conjugated to an
anti-FRβ antibody has been reported to reduce the progression of atherosclerotic lesions
in younger and older individuals (97).

1.8.5. Other
Acetylated low-density lipoprotein (AcLDL) is taken up by macrophages via
scavenger receptors. One study investigated the delivery of AZT, an anti-HIV agent, to
macrophages using AcLDL (98). Since the incorporation of AZT into AcLDL was found to
be low, a prodrug was synthesized. Two cell lines expressing scavenger receptors were
used to evaluate cellular uptake: J774.A (mouse macrophage) and U937 (human
monocyte). A 10-fold increase was found with the AcLDL/prodrug as compared to the
free drug. Moreover, addition of a 30-fold excess of AcLDL to the culture medium
inhibited the uptake, confirming the specificity of the mechanism. The presence of excess
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AcLDL was found to inhibit the cellular uptake of AcLDL/prodrug by macrophages while
excess high density lipoprotein or low density lipoprotein was found to have little effect,
suggesting that the AcLDL/prodrug complex is taken up into macrophages via the
scavenger receptor (98).
A more indigenous approach to macrophage targeting was adapted recently where
the glucan shell of baker's yeast was used as a delivery vector to successfully ferry the
cargo to the macrophages (99). The β1,3-D-glucan shells loaded with siRNA were
successfully taken up by macrophages through dectin-1 receptor or other glucan
receptor-mediated pathways upon oral delivery of nanoparticles containing as little as
20 μg kg-1 siRNA directed against tumour necrosis factor α (Tnf-α). Its messenger RNA
was depleted in macrophages recovered from the peritoneum, spleen, liver and lung, and
lowered serum Tnf-α levels (99).

1.9.

Inorganic nanoparticles

In biomedical applications, progress in utilizing inorganic nanoparticles has advanced
rapidly due to the extensive amount of work done in the synthesis and modification of the
materials (100-103). The reasons being those inorganic nanoparticles provide a robust
framework in which two or more components can be combined to give multifunctional
capabilities. An example can be seen in polymer-coated superparamagnetic iron oxide
nanoparticles. By conjugating multiple components such as drugs (104), tissue or cell
targeting moieties, or siRNA (105) to the polymeric coating, not only can these
multifunctional nanoparticles deliver drug to specific site, they can also be imaged inside
the body by both magnetic resonance and fluorescence imaging, by conjugating
fluorescent molecules.
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Magnetic resonance imaging (MRI) is a powerful and non-invasive diagnostic
techniques for living organisms based on the interaction of protons with the surrounding
molecules of tissues. The current MRI contrast agents are in the form of either
paramagnetic complexes like gadolinium (Gd3+) or manganese (Mn2+) chelates (106) or
superparamagnetic iron oxide (SPIO) particles which exhibits superparamagnetic
property (107). These contrast agents are used to increase the sensitivity of MRI for
detecting various pathological processes.
Paramagnetic complexes accelerate the longitudinal (T1) relaxation of water protons
and

therefore

exhibit

bright

contrast

in

in

T1

weighted

MRI.

Gadolinium

diethylenetriaminepentaacetate has been the most widely used T1 contrast agent. In
contrast, SPIO nanoparticles accelerate the transverse (T2) relaxation of water protons
and exhibit dark contrast.
To synthesize SPIO, several methods had been explored such as co-precipitation,
microemulsion, thermal decomposition, and hydrothermal synthesis (108). Commercially
used T2 contrast agents, such as Ferridex and Combidex, are synthesized via
co-precipitation method, which involves the simultaneous precipitation of Fe2+ and Fe3+
species in aqueous media, and stabilized with hydrophilic polymers, such as dextran.
SPIO synthesized by co-precipitation method are generally coated with hydrophilic
polymers, making them highly stable under physiological conditions. However, they are
generally polydisperse, poorly crystalline and limited in their capacity of drug loading and
the drug dissociates rapidly after administration intravenously.
Recently, SPIO synthesized by the thermal decomposition method have been
extensively studied, as they are highly uniform, crystalline and size-controllable (109).
These high quality hydrophobic iron oxide nanoparticles have been transferred to the
aqueous phase using amphiphilic polymers, phospholipids, and silica shells.
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1.10. Multifunctional Magnetic Nanoparticles
Recently,

techniques

and

procedures

for

producing

monodispersed

and

size-controllable magnetic nanoparticles have advanced considerably which leads to very
active explorations of the applications of magnetic nanoparticles, including biomedicine.
Because of the potential benefits of multimodal functionality in biomedical applications,
magnetic nanoparticles have been used to design and fabricate multifunctional
nanoparticles.
Currently, there are two strategies to fabricate magnetic nanoparticle-based
multifunctional nanostructures (Figure 3). The first strategy, single magnetic nanoparticle
functionalization, involves attaching drugs, antibodies, proteins and dyes to the surface of
magnetic nanoparticles. The other method integrates the magnetic nanoparticles as well
as other functional nanocomponents into polymer based nanoparticles, to achieve better
stability and more functions. Because they can exhibit several features synergistically
and achieve more than one function simultaneously, such multifunctional magnetic
nanoparticles could have unique advantages in biomedical applications.
For the application of the first strategy, Vancomycin-conjugated monodisperse
iron-platinum (FePt) nanoparticles (FePt@Van conjugates) were manufactured. Bacteria
at low concentrations are hard to detect and usually require long induction times before
further analysis. FePt@Van conjugates can detect Gram-positive bacteria at exceptional
low concentrations ∼101 cfu/mL via polyvalent ligand−receptor interactions (110). After
mixing of FePt@Van conjugates with a solution of bacteria, the aggregation of bacteria
can be observed by electron micrograph when external magnetic field applied in a very
small area. The detection limit of this method is comparable to that of assays based on
polymerase chain reaction (PCR), but this method is faster than when the bacterium
count is low and is particularly useful when PCR is inapplicable.
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Protein, genetic materials, organelles, and cells separation and purification is another
way to use single multifunctional magnetic particles (111, 112). For example, using
dopamine as a robust anchor, the successful synthesis of nitriloacetic acid
(NTA)-terminated magnetic nanoparticles offers a simple and versatile platform for
separating six histidine-tagged protein (113, 114). The target proteins cover the surface
of the nanoparticles effectively and quickly, reducing the overall unoccupied surface area
for nonspecific absorption of proteins thus achieving higher specificity than microparticles.
Moreover, NTA-terminated magnetic nanoparticles can be used without pretreatment of
the cell lysate and these nanoparticles are reusable without losing efficiency.
For the application of the second strategy, in one study, drug delivery, cell targeting,
magnetic manipulation, MRI and fluorescence imaging are simultaneously achieved
using a multifunctional mesoporous silica nanoparticle (115). Mesostructured silica
spheres were labeled with fluorescent dye and coated with hydrophilic groups to prevent
aggregation. Water-insoluble anticancer drugs and SPIO were encapsulated inside and
cancer-specific targeting agents were conjugated to the particle’s surface (115). The
targeting ligand modification increased the drug payload delivery into human cancer cells
relative to that into non-cancerous cells. The potential to simultaneously monitor and
deliver molecules to the targeted tissue region will be highly beneficial for both imaging
and therapeutic purposes.
Hyeon and co-workers have manufactured a combination of magnetic nanoparticles
and gold nanoshells to develop a novel nanomedical platform for diagnostic MRI and
simultaneous photothermal therapy (116). Magnetic gold nanoshells (Mag-GNS)
consisting of gold nanoshells embedded with magnetic Fe3O4 nanoparticles was
fabricated (Figure 4). Amino-modified silica spheres were used to covalently attach
Fe3O4 nanoparticles stabilized with 2-bromo-2-methylpropionic acid through a direct

25

nucleophilic substitution reaction between the bromo groups and the amino groups. Then
gold nanoparticles were attached to silica spheres through residual amino groups.
Eventually, gold nanoshells with embedded Fe3O4 nanoparticles were formed around the
silica spheres, Anti-HER2/neu was also linked on the surface of the Mag-GNS resulting in
the formation of the cancer cell targeting Mag-GNS. SKBR3 breast cancer cells targeted
by these Mag-GNS were able to be detected by a clinical MRI system and selectively
killed by near infrared (NIR) radiation. Especially, the targeted cancer cells were rapidly
destroyed upon their short exposure to femtosecond laser pulses with an NIR wavelength
and a low power compared to the use of a continuous laser (116).
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F IGURE 1 DIAGRAM OF HIV MATURE VIRIONS
The lipid bilayer is of cellular origin and includes aproximately 72 spikes of the viral
Env glycoproteins and some cellular proteins. The principal structural proteins forming
the core are p17, p24 and p7 (Figure is adapted from Sierra S et al, J Clin Virol. 2005
Dec;34(4):233-44)
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Drug Class

Generic Name (acronyms)

 Nucleoside Reverse transcriptase Inhibitors (NRTIs)
 Abacavir (abacavir sulfate, ABC)
 Didanosine (delayed-release didanosine, ddI)
NRTIs block reverse
transcriptase, an enzyme
HIV needs to make copies of
itself.

 Emtricitabine (FTC)
 Lamivudine (3TC)
 Stavudine (d4T)
 Tenofovir disoproxil fumarate (tenofovir DF, TDF)
 Zidovudine (azidothymidine, AZT, ZDV)

 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
 Delavirdine (delavirdine mesylate, DLV)
 Efavirenz (EFV)
NNRTIs bind to and later
alter reverse transcriptase

 Etravirine (ETR)
 Nevirapine (extended-release nevirapine, NVP)
 Rilpivirine (rilpivirine hydrochloride, RPV)

 Protease Inhibitors (PIs)
 Atazanavir (atazanavir sulfate, ATV)
 Darunavir (darunavir ethanolate, DRV)
PIs block HIV protease,
an enzyme HIV needs to
make
functional
viral
proteins

 Fosamprenavir (fosamprenavir calcium, FPV)
 Indinavir (indinavir sulfate, IDV)
 Nelfinavir (nelfinavir mesylate, NFV)
 Ritonavir (RTV)
 Saquinavir (saquinavir mesylate, SQV)
 Tipranavir (TPV)

 Integrase Inhibitors
Integrase
inhibitors
block HIV integrase, an
enzyme HIV used to
integrate its genome to
host genome.
 Entry Inhibitors
Entry inhibitors block
HIV from entering CD4 cells.

 Dolutegravir (DTG)
 Elvitegravir (EVG)
 Raltegravir (raltegravir potassium, RAL)
 Enfuvirtide (T-20)
 Maraviroc (MVC)

TABLE 1 SUMMARY OF ART APPROVED BY FDA
(Data is from www.aidsinfo.nih.gov)
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F IGURE 2 ROLE OF MACROPHAGES IN HIV-1 INFECTION AND DISEASE PROGRESSION
The number of CD4+ T cells and viral genome copies in plasma during the different
phases of HIV-1 infection are presented in a schematic drawing. The dotted lines indicate
the effects of antiretroviral therapy. The contribution of macrophages to each phase of
HIV-1 infection is indicated below the scheme. (Figure is adapted from Koppensteiner et
al. Retrovirology. 2012 Oct 4;9:82)
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F IGURE 3 TWO STRATEGIES TO FABRICATE
NANOPARTICLES AND THEIR POTENTIAL APPLICATIONS

MULTIFUNCTIONAL

MAGNETIC

(Figure is adapted from Gao J et al. Acc Chem Res. 2009 Aug 18;42(8):1097-107.)

33

34

F IGURE 4 THE SYNTHETIC APPROACH AND TEM IMAGES OF THE PRODUCTS IN EACH
STEP

a) Synthesis of the magnetic gold nanoshells (Mag-GNS). Transmission electron
microscopy images of b) amino-modified silica spheres, c) silica spheres with Fe3O4
nanoparticles immobilized on their surfaces, d) silica spheres with Fe3O4 and gold
nanoparticles immobilized on their surfaces, and e) the Mag-GNS. (Figure is adapted
from Kim J et al. Angew Chem Int Ed Engl. 2006 Nov 27;45(46):7754-8.)
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2. Chapter II. SMART particle
manufacture and
characterization
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2.1. Abstract
Pharmacokinetics and pharmacodynamics study are the major factors that limiting the
investigation of new nanoformulations. Multifunctional magnetite nanocarriers that
integrate therapeutic agents into a single system have attracted considerable interest in
theranostics integrating drug delivery and drug biodistribution. Using MRI to guide
nanomaterial development can improve formulation development efficacy. To this end
small magnetite ART (SMART) particle for treatment of HIV and simultaneously
pharmacokinetics monitor were developed. We describe the fabrication of polymer
nanocarriers co-encapsulating atazanavir (ATV), an HIV protease inhibitor, and
magnetite nanoparticles which were synthesized by thermal decomposition method.
Morphology of the SMART particles was studied by TEM. Drug loading were measured
by high performance liquid chromatography (HPLC) and magnetite levels were measured
by inductively coupled plasma mass spectrometry (ICP-MS). MDM uptake of SMART and
ATV release of SMART from MDM was determined. Relaxivity of SMART in
phosphate-buffered saline (PBS) and MDM was measured to make sure it is an efficient
contrast agent for MRI. The relaxivity of SMART was found to be r2 = 6200.2 (s-1 ml mg-1)
in MDM and r2 = 7052.1 (s-1 ml mg-1) in PBS.

2.2.

Introduction

Treatment for HIV is arduous due to its long duration and multidrug regimens.
Eradication of the HIV-1 in its infected human host will necessitate antiretroviral drug
delivery to viral sanctuaries with the secondary elimination of latent or restricted
infections (117). Therefore, there is an increasing demand for the development of new
compounds and screening of targeted formulation aiming at virus harboring cells. Among
the virus harboring cells, we are particularly interested in macrophages, not only because
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it is one of the major virus reservoirs, also because macrophage can serve as “Trojan
horse” to store and deliver antiretrovius drug to other infected cells when treated with
right particles. The right particles are the particles with size, shape and targeting ligand
that macrophages prefers.
Paul Ehrlich’s “magic bullet” concept reveals the possibility that targeted delivery of
drug with the help of ligand having well defined affinity for specific cells. Normally drug
delivery systems targeting cell type other than mononuclear phagocyte system are
modified to prevent from phagocytosis. Numerous formulations have been developed to
study and optimize their ability to escape monocyte/macrophage clearance. However as
the role of monocytes and macrophages in infectious disease, inﬂammatory diseases and
cancer is better understood, there is a growing interest in targeting these cell for
therapeutically benefit. People gradually realized that phagocytosis process can be
harnessed for targeting drug delivery and greater knowledge of the mechanisms of
binding and uptake has been learned recently. This idea is especially valuable in
treatment of HIV given the fact that macrophages harbor the virus. Macrophages express
a wide range of receptors including FR, scavenger receptors, mannose receptors and
Fc-receptors can be targeted using ligands appending particles.
Targeting nanoparticles can facilitate drug delivery but, to achieve its potential, would
require improved virus-target tissue drug bioavailability. Therefore, rapid noninvasive
determination of targeted antiretroviral drug biodistribution is needed to study the targeting
efficacy of targeting ligand in animal. One major hurdle towards achieving this goal is the
dearth of any means to measure antiretroviral therapy distribution outside of plasma drug
levels (118).
Liposomes and polymer nanoparticles are the two major types of nanoparticles that
have been developed and evaluated for diagnostic and therapeutic purposes. Liposomes
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composed of natural lipids are attractive drug delivery systems because of their high
biocompatibility,

low

immunogenicity,

long

systemic

circulation

and

favorable

pharmacokinetic profile. Specific targeted delivery can easily be achieved by conjugating
a targeting ligand to the lipid molecule (119-121). Liposomal formulations including Doxil
and DaunoXome are approved by FDA for clinical applications (120, 121). However, the
possible intrinsic low drug loading capacity, fast release profiles of hydrophobic drugs
and physical instability of liposomes limit their clinical applications of different drugs (122).
Polymeric nanoparticles composed of synthetic polylactic-co-glycolic acid (PLGA) are
another widely developed/studied drug delivery platform because of their high stability,
relatively high drug loading capacity of all kinds of drugs, biodegradability, low toxicity,
and controlled/sustained drug release profiles. Depending on particle composition, the
drug release profiles of PLGA nanoparticles can be modulated to be within days, weeks
or

even

months

(123-125).

However,

the

biocompatibility/immunogenicity

of

nanoparticles composed of synthetic polymers including PLGA is not as high as
liposomes. Without further chemical modification, PLGA nanoparticles are rapidly
removed from circulation by the MPS, resulting in short systemic circulation (122). In
summary, both liposomes and PLGA nanoparticles are not independently structurally
robust platforms. Thus, lipid-coated polymer nanoparticles, formed by combining
synthetic polymers and natural lipids, have been developed as robust drug delivery
platform to combine the advantages and avoid the disadvantages of liposomes and
polymer nanoparticles (126).
We theorized that one way to achieve this is by combinations of imaging agent and
ART in a single nanoparticle. If realized, such multicomponent nanoparticle could permit
rapid pharmacokinetic and pharmacodynamics evaluations of ART in virus-target tissues,
such as the lymph nodes and brain. Recent years, SPIO nanoparticles also referred to as
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magnetite have gained large attention due to its minimal toxicity proﬁle and intrinsic
superparamagnetic properties. The superparamagnetism magnetite exhibits make them
respond to external magnetic field, which allow noninvasive tracking through MRI.
Therefore we combined small magnetite and ART into a single nanoparticle and made
SMART particle. By using the SMART particle, ART drug biodistribution would readily be
quantitated by a conventional MRI scan. Such an approach would also provide the
potential of delivering packaged medicines to sites of limited viral growth and serve, in
part, to eliminate the viral reservoir. The approach was previously used for magnetically
targeted cancer drug delivery utilizing T2- or T2*-quantification by MRI (127-130).
To perform proof-of-concept studies we placed magnetite into lipid-coated PLGA
nanoparticles with a commonly used antiretroviral protease inhibitor, ATV. The versatility
of PLGA systems in terms of vesicle size, shape, composition and bilayer fluidity render
them ability to incorporate a wide range of drugs and contrast agents like magnetite, and
ability to carry cell-specific ligands (131). By combining PLGA, drug and magnetite,
organic/inorganic hybrid composite biomaterials allowed drug distribution assessments
with therapeutic ART delivery through a single MRI scan (132). SMART nanoparticles
were screened for optimal uptake and retention in MDMs. This facilitated studies
investigating the dynamics of in vivo drug tissue distribution. Collectively, the work
provides the groundwork for the implementation of SMART systems for noninvasive drug
PK for the inevitable goal of viral elimination.
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2.3. Experimental Procedure
2.3.1. Synthesis Of SPIO
The magnetite particles were synthesized as follows: 6 mmol tris(acetylacetonato)
iron(III) was mixed with 30 mmol 1,2-hexadecanediol, 18 mmol oleic acid, 18 mmol
olylamine and 60 mL benzyl ether in a three-neck round-bottomed flask equipped with
condenser, magnetic stirrer, thermograph and heating mantle and stirred under nitrogen.
The mixture was slowly heated to 110oC and kept at that temperature for 1 hour, then
slowly heated to 200oC. Reflux was kept after it reached 200oC for 2 hours, then slowly
heated to 298oC and kept at reflux for another 1.5 hours. After cooling to room
temperature, a dark homogeneous colloidal suspension was obtained. The suspension
was precipitated in ethanol with a magnetic field. The black precipitate was dissolved in
hexane with the presence of oleic acid and oleylamine and the solution was centrifuged
at 3,800 x g for 10 min to remove any undispersed residue. The black solution was
re-precipitated in ethanol and centrifuged at 10,000 x g for 30 min. Solid products were
obtained by drying the precipitate under vacuum, generating the final dry particles.

2.3.2. Preparation of SMART particle
Preparation of the drug loaded 1,2-Distearoyl-sn-glycero-3-phosphorylcholine (DSPC)
/mPEG-DSPE shell and PLGA core particle was as follows. First, a weighed amount of
PLGA, ATV and magnetite were dissolved in chloroform (oil phase) with a weight ratio of
magnetite to ATV of 1:3. Second, the aqueous phase was prepared by hydration of
DSPC and mPEG-DSPE films. The oil phase was added to the DSPC and mPEG-DSPE
aqueous solution drop-by-drop with constant stirring then sonicated for 60 seconds
followed by a 20 second break under an ice bath. This procedure was repeated for three
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cycles. Chloroform was then removed by stirring overnight. Third, the particle suspension
was centrifuged at 500 x g for 5 min. The supernatant fluids were collected to remove the
aggregated nanoparticles. A high speed 50,000 x g centrifugation for 20 min was used to
collect the nanoparticles. After washing twice with PBS, the nanoparticles were
resuspended.

2.3.3. SMART size, surface charge and size distribution
SMART size and size distribution were measured by dynamic light scattering (DLS,
90Plus, Brookhaven Instruments Co. USA).The surface charge of the SMART particles
was determined by ZetaPlus, a zeta-potential analyzer (Brookhaven Instruments Co.
USA). The pH value and concentration of the particles dispersion were fixed before
measurements of zeta potentials.

2.3.4. Morphology of the SMART particles
The shape and surface morphology of the SMART particles were investigated by
transmission electron microscopy (TEM) performed as previously described (133).
Samples were prepared from dilutions in distilled water of particle suspensions and
dropped onto stubs. After air drying the particles were coated with a thin layer of gold
then examined by TEM. The magnetic properties were determined by a Physical Property
Measurement System.
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2.3.5. SMART particle stability and release of drug in isotonic solution
SMART particles were dispersed in PBS and placed into a 10 k dialysis tube in 2 L
PBS under stirring at 37oC. At 30 min and 1, 2, 3, 4, 6, 8 and 10 days, 100 µl of the
suspension was collected. The supernatant was dissolved in 100 µl tetrahydrofuran
(THF)/methanol (volume ratio 1:10) mixture. The amount of ATV and magnetite was
measured by high-performance liquid chromatography (HPLC) and ICP-MS, respectively
(133, 134).

2.3.6. Human monocyte isolation and cultivation
Human peripheral blood monocytes were obtained by leukapheresis from HIV-1 and
hepatitis seronegative donors and purified by counter-current centrifugal elutriation (135).
The cells were cultured at a concentration of 1 × 106 cells/ml at 37oC in a humidified
atmosphere (5% CO2) in DMEM supplemented with 10% heat-inactivated pooled human
serum, 1% glutamine, 50 µg/ml gentamicin, 10 µg/ml ciprofloxacin and 1000 U/ml
recombinant human MCSF for 7 to 10 days until differentiation into macrophages
occurred.

2.3.7. SMART uptake and retention by MDM
After differentiation, MDM were treated with 100 μM SMART particles, based upon
ATV content. Uptake of SMART particles was assessed without medium change for 8
hours. Adherent MDM were collected by scraping into PBS, at 1, 2, 4 and 8 hours after
treatment. Cells were pelleted by centrifugation at 500 x g for 8 min at 4°C. Cell pellets
were briefly sonicated in 200 μl of methanol/acetonitrile (1:1) and centrifuged at 20,000 x
g for 10 min at 4°C. To determine cell retention of SMART particles, MDM were exposed
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to 100 μM SMART particles for 8 hours, washed 3x with PBS, and fresh media without
particles was added. MDM were cultured for an additional 15 days with half medium
exchanges every other day. On days 1, 5, 10 and 15 after SMART treatment, MDM were
collected as described for cell uptake. Cell extracts were stored at -80°C until HPLC and
ICP-MS analysis (133).

2.3.8. Prussian blue staining of MDM retained SMART particles
MDM were treated with 100 μM SMART particles for 24 hours. Adherent MDM were
washed 3x with PBS. Cells were fixed with 2% formalin/2.5% glutaraldehyde in PBS for
10 min then washed 2x with PBS. Fixed macrophages were treated with 5% potassium
ferrocyanide/5% hydrochloric acid (1:1) for 10 min at room temperature. Following
solution aspiration the cells were washed 2x with PBS. Stained cells were examined by
light microscopy.

2.3.9. MRI phantoms and relaxivity measures
After differentiation, MDM were treated with 100 μM SMART particles, based upon
ATV content. Twenty-four hours later the treatment medium was removed and the cells
were washed 3× with 1 ml PBS. Cells were collected and suspended at different cell
concentrations (0-5 x 106 cells/ml) in 1% agar gel. T2-relaxtivity was measured by MRI.
Magnetite content in the cells was quantitated by ICP-MS.
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2.4. Results
2.4.1. Manufacture and characterization of SMART
SMART were composed of a hydrophobic PLGA/ATV/magnetite core and an
amphiphilic DSPC and DSPE-PEG2k lipid shell (Figure 5A). DSPC and DSPE-PEG2k
increased SMART stability and facilitated increased systemic formulation circulation
times. Both ATV and magnetite are distributed homogeneously within the core of the
particle. SMART was made using a single oil-in-water emulsion with lipid surfactants.
After sonication amphiphilic lipids self-assembled to the monolayer surrounding
PLGA/ATV/magnetite containing oil droplets, achieved through hydrophobic interactions.
Evaporation of chloroform under continuous magnetic stirring allowed for the formation of
lipid-coated

solid

PLGA/ATV/magnetite

core.

SMART

was

then

purified

by

ultracentrifugation before further characterization. DLS results showed that the average
size of the particles is 268 nm with a polydispersity index (PDI) of 0.2. TEM was
employed to obtain the image that best reflects SMART particle morphology (Figure 5B,
right panel). This illustrated that the particles were spherical in shape with narrow size
distributions. A representative particle is shown by TEM, showing the SPIO contained
within the particle’s core. Our preliminary in vitro results showed that SMART is very
stable and ATV can slowly release from SMART up to 10 days.

2.4.2. SMART uptake, antiretroviral drug release and Prussian blue staining
After SMART particle characterizations were completed, the in vitro kinetics of MDM
uptake and retention were determined. Our previous studies of nanoformulated ART
(nanoART) uptake in MDM showed that > 95% of total uptake occurs by 8 hours for ATV
nanoART (136-138). Up to 2 μg of ATV/ 106 cells was recorded in MDM at 8 hours with
magnetite uptake reflective of particle composition (Figure 5C). The majority of the cells
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took up the magnetite as observed through Prussian blue staining (Figure 5D). Indeed,
such staining demonstrated that magnetite-containing particles were readily incorporated
in macrophages by 8 hours. The controlled and sustained release profile or ATV
facilitates the application of the SMART particles for the delivery of antiretroviral drugs.

2.4.3. Measures of SMART particle relaxivity
Presence of SMART particles causing increased relaxivity (R2 (s-1)) in tissue as a
function of concentration (expressed as mg/ml magnetite). Concentration dependent
relaxivity [r2 (s-1 ml mg-1)] were determined using phantoms consisting of both free
SMART particles (Figure 6A) and SMART particles taken up by MDM (Figure 6B). The
magnetite concentrations in mg/ml contained by SMART in 1% agar gels were plotted
against R2 as measured by MRI. The relationship between R2 and magnetite
concentration of SMART in phantoms was linear within the range of the measured
magnetite concentrations. The concentration dependent relaxivity of SMART was found
to be r2 = 6200.2 (s-1 ml mg-1) in MDM and r2 = 7052.1 (s-1 ml mg-1) in PBS. The r2 of
SMART in MDM was used for noninvasive in vivo quantitation of magnetite concentration
due to SMART influx using MRI in next chapter.

2.5. Discussion
The principle goal in developing this polymer system rests in the ability to utilize MRI
scans to rapidly assess cell and tissue drug biodistribution. The idea is that the
polymer-encased dual magnetite and drug particle would permit a clear determination of
drug levels in virus-target tissues in a very short time interval. However, a hybrid particle
is hard to manufacture due to the different nature of the components. So it is important to
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find the right composition. More magnetite will interfere with the incorporation of the ART
drug, on the other hand, less magnetite will cause inefficient MRI signal. After testing
different condition for drug release and relaxivity, we identified that the best drug vs
magnetite ratio is 3:1, in which particles has slow drug release while has adequate
magnetite to generate MRI signal.
Our DLS results showed that the average size of the particles is 268 nm with a PDI of
0.2. The narrow size distribution is linked to the DSPC, which serves to stabilize the
polymeric SMART in the aqueous phase. The zeta potential of the particles is -45.2 mV,
which provides its stability when suspended in aqueous media. Although DSPC is neutral
when it is used as a particle coat it exhibits non-zero mobility in an external electric field.
This may result in a higher negative charge since some anions bind to the neutral lipids
making the surface more negatively charged.
The magnetite showed as a solid black dot on TEM picture of the SMART particles
(Fig.4 B). Not only it can be found inside the SMART, but also small amount of magnetite
attached to the surface of the SMART particles. It may be free magnetite that were
trapped in between the polymer.
The relaxivity is an important factor to study a MRI contrast agent. Concentration
dependent relaxivity of SMART in PBS and MDM showed slightly different result (7052 s-1
ml mg-1 vs 6200 s-1 ml mg-1). It may be caused by the oxidization of magnetite during the
24 hours incubation with MDM. The regression of relaxivity in PBS is better than that in
MDM (0.998 vs 0.961). It’s possible that it’s hard for the cell to reach homogeneous
suspension in 1% agar gel.
The cell-based carriage and delivery of antiretroviral drugs to sites of active HIV-1
replication can facilitate slow release of drug for time periods measured in weeks or
perhaps months. As the monocyte-macrophage is a cell target for HIV growth, the added
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benefit rests in the abilities to bring ART to subcellular sites of viral assembly. The next
step would be to evaluate the correlation between magnetite and ATV after injected to the
mice.
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F IGURE 5 DEVELOPMENT OF SMART NANOPARTICLES
(A) The schematic structure of lipid-coated PLGA SMART. ATV and SPIO are well
distributed within the PLGA matrix to form the core of SMART. The PLGA core is coated
with lipid monolayer to form the shell of SMART. (B) Representative TEM of a single
SMART particle. (C) Time course of uptake (upper panel) and retention (lower panel) of
SMART in MDM., MDM were treated with 100 µM SMART (based on ATV content) for 1,
2, 4 and 8 hour uptake studies. For cell retention MDM were treated with 100 µM SMART
for 8 hours, cell culture media was changed and cells were cultured for an additional 15
days. The cell lysates at indicated times were analyzed by HPLC and ICP-MS for ATV
and magnetite quantification, respectively. Data represent the mean ± SEM, n = 3, for
each time point. (D) Prussian blue staining of MDM. MDM were treated with PBS
(negative control, upper panel) or 100 µM SMART (lower panel) for 24 hours, and then
fixed with 2% formalin/2.5% glutaraldehyde and stained with 5% potassium
ferrocyanide/5% hydrochloric acid (1:1).
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F IGURE 6 CONCENTRATION DEPENDENCE OF RELAXIVITY OF SMART
Concentration dependence of relaxivity (r2) of SMART in (A) PBS and (B) MDM. MDM
were incubated with 100 µM SMART (based on ATV content) for 24 hours. Collected
MDM and SMART were suspended in 1% agar gel. T2 was measured by MRI and
magnetite content by ICP-MS
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3. Chapter III SMART:
MRI-assayed drug and
magnetite biodistribution
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3.1.

Abstract

The feasibility of imaging SMART biodistribution in vivo using MRI was investigated in
this chapter. In this proof-of-concept study, the jugular vein was used for the intravenous
injections of SMART and ensures uniform drug and magnetite distribution, minimizes
standard deviation within groups and provides rapid particle distribution. The relationship
between magnetite concentration and ATV concentration in different organs in different
time points was evaluated. We demonstrated reduction of T2* caused by magnetite’s
presence in tissues correlates with the drug content.
The magnetite concentration was quantified from the change in T2 weighted relaxivity
(R2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite relaxivity (r2)
determined as the slope of magnetite concentration versus R2 in phantom studies. ATV
concentrations was quantified by ultra performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS) following the MRI scan.
Our immunohistochemical analysis further demonstrates that SMART particles are
taken up by liver and spleen macrophages. These cells serve as the reservoir of SMART
particles, as well as the major targets of HIV. The advantages of using SMART rests as a
cassette system for testing nanoparticles that direct nanoART to tissue viral reservoirs.

3.2.

Introduction

The visualization of cellular function in living organisms is not a new modality (139,
140). Optical, X-ray, nuclear, MRI and ultrasound allows three-dimensional whole-body
scans at high spatial resolution and are adept at morphological and functional evaluations.
The data obtained can be enhanced by magnetite and improved image resolution. By
immobilizing a specific target molecule on the surface of a magnetic particle, the
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molecule inherits its magnetic property. Magnetic tissue targeting using multifunctional
carrier particles can also facilitate effective treatments by enabling site-directed
therapeutic outcomes.
Our current work sought to use lipid coated PLGA SMART to encase magnetite and
antiretroviral therapy to facilitate MDM uptake of drug and its subsequent slow release. In
the last chapter we discussed the synthesis of SMART to facilitate drug screening for
specific targeting ligands or sugars. In this chapter we are going to study the
biodistribution of SMART and correlation between drug and magnetite concentration. A
summary cartoon of the experiment scheme can be seen in Figure 7. We also stained the
paraffin embedded tissue with Iba-1 antibody to label macrophages and Prussian blue to
reveal iron in liver and spleen.

3.3.

Experimental Procedures

3.3.1. SMART biodistribution
Biodistribution of SMART particles was determined in male Balb/cJ mice (Jackson
Labs, Bar Harbor, ME). SMART particles at a dose of 30 mg/kg ATV were injected via a
jugular vein cannula in a total volume of 100 μl for each mouse. The mice were scanned
two hours before injection then continuously at 0.25, 1, 2 and 4 hours or at 24 hours after
SMART administration. Tissues were collected following the final MRI scan. Tissue drug
levels were quantitated by UPLC-MS/MS (141) and magnetite levels were determined by
ICP-MS as previously described (134).
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3.3.2. MRI acquisition
MRI was acquired using a 7T/16cm Bruker (Ettlingen, Germany) Pharmascan
MRI/MRS scanner and a commercial mouse body resonator. SMART detection by MRI
was done using T2 mapping for quantitation and T2* weighted high resolution imaging for
detection of biodistribution throughout the body. The sequence used for T 2 mapping was
a Carr-Purcell-Meiboom-Gill (CPMG) phase cycled multislice multiecho sequence.
Forty-one 0.5 mm thick contiguous interleaved coronal images were acquired with an
acquisition matrix of 256 x 192, 40 mm field of view, 12 echoes at 10 ms first echo time
and 10 ms echo spacing, repetition time of 4680 ms, three averages, for a total
acquisition time of 30 min. T2* weighted MRI was acquired using a 3D spoiled gradient
recalled echo sequence with echo time = 3 ms, repetition time = 10 ms, 15 degree pulse
angle, 50 x 40 x 30 mm FOV, 256 x 196 x 128 acquisition matrix, six averages, for a total
scan time of 25min.

3.3.3. MRI analyses
T2 maps were reconstructed using custom programs written in Interactive Data
Language (IDL; Exelis Visual Information Solutions, McLean, VA). Preinjection and 24
hour postinjection maps were constructed using the even-echo images from the CPMG
phase cycled imaging data set. Mean tissue T2 was determined using region of interest
(ROI) analyses before and after SMART injection for the 24 hour results. Magnetite
concentration was then determined from the change in relaxivity (R2 = 1/T2preinjection 1/T2postinjection) and the per milligram magnetite of SMART particle relaxivity (r2) determined
as the slope of magnetite concentration versus R2 in phantom studies.
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Acute (0-4 hour) data were acquired with in-magnet jugular vein injection, allowing
sequential T2 mapping to be acquired with a T2* weighted fast low angle shot (FLASH)
image acquired at the end of a four-hour period. The natural coregistration of these data
allowed development of magnetite concentration maps based on relaxivity changes using
custom programs written in IDL for the acute scanning session. The ROI analyses were
performed using ImageJ (http://imagej.nih.gov/lj) software. For analysis of the acute
study, the windows synchronize option was used to simultaneously draw ROIs at same
locations on all concentration maps at different time points.

3.3.4. Immunohistochemical identification of cell-SMART uptake
To determine cell localization of SMART spleen and liver were collected after the final
MRI scan and fixed in 10% neutral buffered formalin. Tissues were paraffin embedded
and sectioned at 5 µm. To identify macrophages, sections were incubated with antibody
to ionized calcium binding adaptor molecule 1 (Iba-1, Wako Chemicals USA, Inc.,
Richmond, VA). The polymer-based HRP-conjugated anti-mouse and anti-rabbit Dako
EnVision were used as secondary detection reagents and color developed with
3,3'-diaminobenzidine (DAB). All paraffin-embedded sections were stained with Prussian
blue to identify magnetite content. Slides were imaged using a Nuance light microscopy
system for brightfield imaging.

3.4.

Results

3.4.1. Real time SMART biodistribution and pharmacokinetics
Magnetite labeling allowed the distribution of SMART particles to be quantified over
time in live animals (Figure 8). Figure 8A shows examples of magnetite concentration
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from magnetite in SMART, constructed from MRI T2 maps measured before and
continuously every 30 minutes for four hours after SMART injection. ROI analyses of
these data from six animals are shown in Figure 8B. A significant amount of the SMART
is still within the vasculature, largely leading to the intensity in the kidney, as kidney
shows very little uptake by 24 hours. This reflects the measured concentration in kidney
reducing over the first four hours while in liver and spleen, organs where SMART
accumulates, the mean signal is relatively constant or increases as the particles
redistribute from the blood to the tissue. Significant accumulation of SMART was found in
liver and spleen at 4 hours as can be appreciated in Figure 9.
Figure 9 displays two of the 0.128 mm thick T2* weighted high-resolution 3D FLASH
images of the same mouse before and 4 hours after injection of SMART. Presence of
magnetite in tissue causes a reduction of T2* to the point of complete signal loss at TE = 3
ms in the liver, spleen, and some abdominal regions. This method is not quantitative,
however it does allow ready identification of the presence of magnetite throughout the
body, which can be used to guide quantitative ROI analyses using T2 maps.

3.4.2. Correlation between magnetite and drug tissue content
Figure 10 shows the relationship between magnetite concentration and ATV
concentration of liver, spleen and kidney in four animals 24 hours after injection. It can be
appreciated that there is a significant positive correlation (Pearson Correlation, r=0.786,
p=0.0008). These results demonstrate the capability of MRI to be used for monitoring
nanoART distribution.
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3.4.3. Identification of magnetite-ART relationships in systemic tissues
We reasoned that cellular biodistribution of SMART was concordant with our prior
results with nanoART (142). To prove this theory we next studied the relationships
between SMART particle biodistribution and macrophages in mice following parenteral
SMART injections. Animals were sacrificed 24 hours after injection and tissues were
collected. Dual Iba-1 for macrophages and Prussian blue staining for magnetite were
performed and evaluated by bright field microscopic imaging. Prussian blue staining was
nearly exclusively in tissue cells identified as macrophages in liver. Spleen from mice
without SMART treatment showed Prussian blue staining but staining increased when
compared with mice received SMART treatment. As shown in Figure 11, Iba-1 positive
macrophages were readily seen in both liver and spleen in parallel to distribution of
Prussian blue. The dual staining pictures showed that the SMART particles were retained
in tissue macrophages.

3.5. Discussion
The overarching idea of this chapter is to use SMART as a cassette system for testing
ligands conjugated to particles for improved targeting of viral reservoirs such as the
lymph nodes and brain. To this end, we selected DSPC and DSPE-PEG2k as the shell
and PLGA as the core of SMART system. DSPC is used to increase the biocompatibility
of SMART, and DSPE-PEG2k is used to build a sterically repulsive shield around SMART
that reduces opsonization, prevents interactions with the MPS, escape renal exclusion,
and increases systemic circulation. To the best of our knowledge, this is the first attempt
to develop lipid-coated PLGA nanoparticles for HIV therapeutics.
After pre-scan, mice were scanned by MRI continuously at 30 minute intervals up to 4
hours after SMART administration. Magnetite levels in kidney, spleen and liver were
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similar in the first half hour due to the magnetite is still circulating in the blood stream
following SMART administration (Figure 8B). Yet as magnetite started to distribute over
time, a higher amount stayed in liver and spleen after 4 hours of injection, correlated with
higher concentration of magnetite in these organs at 24 hours as shown by the MRI
scans. Our in vivo MRI results also showed that the concentrations of magnetite and ATV
in mouse tissues, such as liver, spleen and kidney, correlate with one another at 24 h
after injection.
The results support the idea that SMART technology facilitates the noninvasive
evaluation of drug PK and biodistribution in virus target tissues by MRI. These results
demonstrate the capability of MRI to be used for monitoring ATV distribution by tracking
the presence of magnetite in tissue, which causes a reduction of T2*. Our in vivo MRI
results clearly demonstrated that SMART could facilitate the noninvasive evaluation of
drug PK and biodistribution in different tissues and provide rapid assessments for the
next generation cell and tissue ligand decorated particles.
Erythrocyte hemoglobin and its breakdown products are a substantive source of iron.
These are degraded after the lifespan of the erythrocyte (143). This occurs predominantly
in the spleen with iron transferred back into the blood. The highly vascularized spleen
contains easily seen red blood cell breakdown products including iron that are
phagocytized by macrophages (144). Thus, the total iron content in the spleen is readily
visualized by Prussian blue staining but substantively increased after SMART treatments
(Figure 11 G and H). The iron content in spleen also changed from 228 µg/g before
treatment to 356 µg/g after treatment, measured by ICP-MS.
Notably, there is a considerable focus amongst HIV/AIDS researchers towards the
development of reliable methods to bring drugs to reservoir sites with the explicit goal of
eliminating virus. Targeted drug when combined with suitable imaging techniques like
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SMART particles could facilitate this goal by providing a “go/no go” for treatment success.
This technology clearly opens new opportunities to develop platforms that would
accelerate elimination of viral infections.
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F IGURE 7 CARTOONS OF SMART INJECTION AND BIODISTRIBUTION
(A) MRI of mice were obtained and SMART was injected to mice through jugular vein.
(B) SMART was taken up by MDM in vivo. (C) 24 hours later, MRI of mice were obtained.
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F IGURE 8 MRI ASSESSMENTS OF THE TISSUE
PHARMACOKINETICS BY SMART PARTICLES

DRUG

BIODISTRIBUTION

AND

MRI assessments of the tissue drug biodistribution and pharmacokinetics by SMART
particles. After pre-MRI scan, mice were injected with SMART through a jugular vein
cannula, and then scanned by MRI at continuously at 30 minute intervals up to 4 hours
after SMART administration. Mean tissue SMART content was determined as detailed in
Materials and Methods. Immediately after the final scan, mice were euthanized and
tissues were collected for ATV quantification by UPLC-MS/MS. (A) MRI based images of
magnetite concentration in kidney, spleen and liver from 0.5 h to 4 h following SMART
administration. (B) Mean ± SEM (n=6) of magnetite levels in kidney, spleen and liver over
4h following SMART administration.
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F IGURE 9 3D GRADIENT RECALLED ECHO IMAGES OF THE SAME MOUSE BEFORE AND
AFTER INJECTION OF SMART
3D gradient recalled echo images of the same mouse before (A) and 4 hours after (B)
injection of SMART. It can be appreciated that the signal from the liver is completely
eliminated due to the accumulation of magnetite loaded SMART (L=lung, Lv=liver,
K=kidney and S=spleen).
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F IGURE 10 CORRELATION OF SMART- ASSOCIATED MAGNETITE AND ATV IN TISSUES
24 HOURS AFTER ADMINISTRATION
The magnetite concentration was quantified from the change in T2 weighted relaxivity
(R2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite relaxivity (r2)
determined as the slope of magnetite concentration versus R2 in SMART phantom
studies. ATV concentrations were quantified by UPLC-MS/MS following the final 24 hour
MRI scan.
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F IGURE 11 IMMUNOHISTOLOGY OF I BA-1 STAINING AND PRUSSIAN BLUE STAINING
Immunohistology of Iba-1 staining and Prussian blue staining of (A) Liver from control
mice with Prussian blue (200×). (B) Liver from SMART treated mice with Prussian blue
(200×). (C) Liver from SMART treated mice with Prussian blue and Iba-1 (200×). (D)
Enlargement from indicated section in C. (E) Spleen from SMART treated mice with
Prussian blue (200×). (F) Spleen from SMART treated mice with Prussian blue and Iba-1
(200×). (G) Enlargement from indicated section in F. (H) Spleen from control mice with
Prussian blue and Iba-1 (400×). Livers and spleens were fixed with 10% formalin, paraffin
embedded and sectioned for immunohistological analysis after the final MRI scan.
Macrophages were identified by Iba1 stains (brown) and magnetite identified by Prussian
blue. Fl=lymphoid follicle, M=marginal zone.
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4. Chapter IV APM and FAPM
manufacture and
characterization
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4.1. Abstract
Dextran-based SPIO nanoparticles have been extensively used clinically as MRI
contrast agents. These dextran-based SPIO nanoparticles are taken up by phagocytic
cells and accumulate in the reticuloendothelial system. These nanoparticles can be
utilized for multifunctional biomedical applications with simultaneous drug-delivery and
imaging capabilities. However, dextran coating is not strongly associated with SPIO
nanoparticles and can be readily detached, leading to SPIO aggregation and precipitation
under physiological conditions (145). Also, the lack of functional groups on the surface of
PLGA nanoparticles for covalent modification has limited their potential for surface
tethering targeting ligands (146). Additionally, these dextran-based SPIO nanoparticles
are limited in their capacity of drug loading and the drug dissociates rapidly after
administration intravenously (147).
In this study, we describe the development of single magnetite nanoparticles with
strong polymer coating for MRI. The developed nanoparticles are composed of a
hydrophobic 10 nm magnetite core and a PEG coating, anchored with a bisphosphate
drug, Alendronate (ALN). The study was designed to investigate the characteristics and
biodistribution of the developed SPIO. Size, shape, charge, morphology, relaxivity and
stability of ALN-PEG coated magnetite (APM) and ALN-PEG-folate coated magnetite
(FAPM) were evaluated.
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4.2. Introduction
Significant reductions of residual HIV from its cell and tissue reservoirs in brain,
lymphoid tissues, bone marrow, gastrointestinal and the genital tracts can be achieved by
chemical or immunological means. One way to achieve this goal is through viral
reservoir-targeted long-acting antiretroviral nanoparticles by monocyte-macrophage drug
targeting (148). To facilitate such an end, a number of ligands for macrophage targeting
are being developed and include peptides (68), antibodies (87), proteins and sugars (78)
that make use of cell-specific receptor expression or by enabling phagocytosis. An
additional hurdle towards achieving this goal is the dearth of ways to measure ART
distribution outside of plasma drug levels (118).
In particular pharmacokinetic and pharmacodynamics studies have recently
demonstrated the benefit of such targeting strategies; although assessments of such
drug biodistribution improvements have entailed intensive tissue analyses (149). We
posit that such processes can be improved further by targeting ligand testing of linked
magnetic nanoparticles and parallel MRI evaluation of particle distribution. Moreover, we
theorize that such results would closely mimic drug tissue biodistribution.
Prior magnetite platforms have been developed for this purpose (150-152). Among
them, polysaccharides are the most widely studied coating materials for magnetite
(153-155). However, the potential in vivo coating disassociation and bare magnetic
particle exposure causing cellular toxicity are of significant concern (156). Another
limitation of current coating materials for magnetite is the complicated conjugation
strategies or limited appreciated functional groups for specific ligand decoration in
magnetite. Substantive efforts have been made to resolve these issues. ALN is a
bisphosphonate drug, which is clinically used to treat osteoporosis. The P-C-P structure
of bisphosphonates is known for its ability to bind divalent metal ions, such as Ca2+ (157).
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Taking advantages of this metal binding ability, we successfully conjugated ALN into
polymers for stable magnetic particle coating. FA is a targeting ligand of FR, which
expression is restricted to few cell types including macrophages. FA was successfully
decorated to the exterior coating of magnetite to allow comparisons of magnetite
biodistribution with and without targeting.

4.3. Experimental Procedures
4.3.1. Synthesis of magnetite
The magnetite particles were synthesized as follows: 6 mmol tris(acetylacetonato)
iron(III) was mixed with 30 mmol 1,2-hexadecanediol, 18 mmol oleic acid, 18 mmol
olylamine and 60 ml benzyl ether in a three-neck round-bottomed flask equipped with
condenser, magnetic stirrer, thermograph and heating mantle and stirred under nitrogen.
The mixture was slowly heated to 110oC and kept at that temperature for 1 hour, then
gradually heated to 200oC. Reflux was kept after it reached 200oC for 2 hours, then slowly
heated to 298oC and kept at reflux for another 1.5 hours. After cooling to room
temperature, a dark homogeneous colloidal suspension was obtained. The suspension
was precipitated in ethanol with a magnetic field. The black precipitate was dissolved in
hexane with the presence of oleic acid and oleylamine and the solution was centrifuged
at 3,800 x g for 10 min to remove any undispersed residue. The black solution was
re-precipitated in ethanol and centrifuged at 10,000 x g for 30 min. Solid products were
obtained by drying the precipitate under vacuum, generating the final dry particles.
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4.3.2. Synthesis of alendronate conjugated polyethylene glycol (ALN-PEG)
Polyethylene glycol monomethyl ether 5,000 (mPEG5k) (1 g, 0.2 mmol) was
dissolved in anhydrous dichloromethane (5 mL) together with 4-dimethylaminopyridine
(12 mg, 0.1 mmol) and triethylamine (101 mg, 1 mmol). The mixture was cooled to 0°C,
and p-toluenesulfonyl chloride (Tos-Cl) (0.191 g, 1 mmol) was added. Next, the mixture
was incubated overnight at room temperature and the mixture precipitated in ether. The
precipitate (crude product) was purified using a LH-20 column with methanol as the
eluent. The yield of p-toluenesulfonyl-terminated mPEG5k (Tos-PEG) was 65%.
Tos-PEG (0.52 g, 0.1 mmol) was dissolved in dimethylformamide (5 mL). Sodium azide
(65 mg, 1 mmol) was then added. The reaction proceeded with stirring at 100°C for 1 day.
After filtration and solvent removal, the crude product was dissolved in dichloromethane
and precipitated into ether. The precipitate (crude product) was further purified using a
LH-20 column with methanol as the eluent. The yield of azide-terminated PEG5k
(azido-PEG) was 70%.
Azido-PEG

(0.25

g,

0.05

mmol)

and

1-hydroxy-4-pent-4-ynamidobutane-1,

1-diyldiphosphonic acid (40 mg, 0.1 mmol) were dissolved in an ethanol-H2O solution
(1/1 v/v, 2 mL). Sodium ascorbate (19.8 g, 0.1 mmol) and copper sulfide pentahydrate
(2.5 mg, 10 μmol) were then added separately under argon. The reaction mixture was
stirred for 3 days at room temperature. After removal of the solvent, the crude product
was acidified and purified using a LH-20 column with methanol as the eluent. The yield of
the ALN conjugated polyethylene glycol (ALN-PEG) was 70%.
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4.3.3. Synthesis of FA conjugated ALN-PEG (ALN-PEG-FA)
Alendronate sodium trihydrate (1g, 3 mmol) was dissolved into 5 ml water, the pH
was adjusted to around 8.0 with NaOH, Fmoc-PEG5k-N-hydroxysuccinimide (NHS) (0.5
g, ~ 1 mmol) was then slowly added into ALN solution. The reaction solution was stirred
overnight at room temperature, and then dialyzed to remove excess ALN. After
lyophilization, the resulting ALN-PEG-Fmoc powder (0.35 g) was directly dissolved in
20% piperidine in THF and reacted at room temperature for 2 hours to deprotect Fmoc.
The solvent was concentrated using rotavapor under vacuum, and precipitated into ether.
The resulting precipitate (ALN-PEG-NH2) was further purified with dialysis and
lyophilization.
FA (110 mg, 0.25 mmol) was dissolved in 2 ml DMSO plus 50 ul of triethylamine. A
1.1 molar ratio of NHS (31 mg) and N,N’-dicyclohexylcarbodiimide (DCC; 57 mg) was
added. The mixture was stirred 4 hours at room temperature in the dark. The by-product,
dicyclohexylurea, was removed by filtration. ALN-PEG-NH2 (0.25 g) was then added into
the NHS-folate solution for overnight conjugation at room temperature in the dark. The
crude product was precipitated with diethylether, and further purified by dialysis.
CF633-NHS (1umol) and ALN-PEG-NH2 (10 mg) were dissolved in 0.5 ml
dimethylsulfoxide (DMSO), and then reacted overnight in dark at room temperature. The
resulting CF633-labeled ALN-PEG was purified using a LH-20 column with methanol as
the eluent.

4.3.4. Coating of ALN-PEG and ALN-PEG-FA onto magnetite (APM and FAPM)
To synthesize APM, various amount of ALN-PEG polymer (5, 10, 20, 50 mg) was
dissolved in 0.5 ml deionized water separately; 5 mg magnetite was dissolved in 10 ml
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THF. Polymer solution was added slowly to magnetite THF dispersion with stirring. The
mixture was stirred overnight, and then THF was removed using rotary evaporator. The
crude product was dissolved in 5 ml deionized water, and then centrifuged at 500 x g for
10 min to remove uncoated magnetite. Non-coated polymer was removed by dialysis
using 25k dialysis tubing overnight. After dialysis, the dispersion was lyophilized to obtain
APM. The mass ratios between magnetite and coating materials were measured using
thermal gravimetric analysis (TGA).
To synthesize FAPM, 16 mg ALN-PEG polymer and 4 mg ALN-PEG-Folate were
dissolved in 0.5 ml deionized water and 5 mg magnetite was dispersed in 10 ml THF.
Polymer solution was added slowly to the magnetite THF dispersion with stirring in the
dark. The mixture was stirred overnight, and then THF was removed using a rotary
evaporator. The crude product was dissolved in 5 ml deionized water, and then
centrifuged at 500 x g for 10 min to remove uncoated magnetite. Non-coated polymers
were removed by dialysis using 25k dialysis tubing overnight in dark. After dialysis the
dispersion was lyophilized to get FAPM powder.
CF633-labeled APM and FAPM were synthesized using the same procedure with 2
mg CF633-labeled ALN-PEG dissolved in the polymer solution.

4.3.5. Physicochemical and stability characterization of APM and FAPM
Particles size and size distribution were measured by DLS using a Malvern Zetasizer
Nano-ZS instrument (Malvern Instruments Inc., Westborough, MA, USA). The pH value
and concentration of the particles dispersion were fixed before measurements of particles
size and size distribution. All measurements were performed at 25°C. The shape and
surface morphology of the APM and FAPM particles were investigated by TEM
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performed as previously described (158). Samples were prepared from dilutions in
distilled water of particle suspensions and dropped onto stubs. After air-drying the
particles were then examined by TEM. The stability of APM was studied in NaCl solutions
(1M and 2M) and buffer solutions with pH 2, 4, 6, 7.4, 8, 10, 12 that were determined by
DLS and TEM. Concentration dependent relaxivity (r2 s-1 ml mg-1) was measured by MRI
of APM or FAPM dispersion in concentrations ranging from 0 µg/ml to 40 µg/ml.

4.3.6. Statistical analyses
The data are presented as mean ± SEM. Statistical significance between groups was
assessed using Student’s t-test by Graph-Pad® Prism unless specified. The data were
considered statistically significant if P<0.05.

4.4. Results
4.4.1. Synthesis of ALN conjugated polyethylene glycol (ALN-PEG) and FA
conjugated ALN-PEG (ALN-PEG-FA)
As an initial step towards securing this end, we manufactured ALN-PEG and
ALN-PEG-FA polymers. These were synthesized for magnetite coating. In order to
efficiently conjugate hydrophilic ALN to PEG polymer, the versatile click reaction was
used (Figure 12A).
mPEG was first tosylated with toluenesulfonyl chloride, then converted to azido-mPEG
under reflux using excess sodium azide. To introduce an acetylene group onto ALN,
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide

hydrochloride/NHS

was

used

to

conjugate ALN and pentynoic acid. Finally, these two fragments were successfully
conjugated together through copper (I)-catalyzed Huisgen 1, 3-dipolar cycloaddition
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between the azide and alkyne with high yield at room temperature. ALN-PEG-FA was
synthesized using amidation strategy (Figure 12B). First, ALN was incorporated into PEG
by reaction with Fmoc-PEG-NHS, and the Fmoc was then deprotected with piperidine to
synthesize amine functionalized ALN-PEG (NH2-PEG-ALN) for ligand conjugation, which
is one of the most attractive properties of ALN-PEG polymers. For folate conjugation,
NHS-activated folate was reacted with NH2-PEG-ALN to synthesize the targeted
ALN-PEG-FA with high yield. From 1H NMR spectrum, emergence of the singlet peak of
1,2,3-triazole at 8.32 ppm verified the successful conjugation of ALN to PEG polymer
(Figure 12C)

4.4.2. Manufacture of APM and FAPM
To confirm the strong coating ability of ALN-PEG polymer to magnetite, oleic acid (OA)
coated magnetite synthesized by thermal decomposition method with an average size in
10 nm were selected for replacement coating. The OA coating material is hydrophobic
and relatively weakly bound to the core of magnetite. OA-coated magnetite was
dispersed into THF, then ALN-PEG was added into this solution for replacement coating
overnight at room temperature and turned the magnetite from hydrophobic to hydrophilic.
At the end of replacement, THF was evaporated and magnetite particles were
redispersed in water and dialyzed. After dialysis, the dispersed solution was lyophilized.
The structure of APM and FAPM is demonstrated in Figure 13.
Benefitting from its high coating efficacy, ALN-PEG was coated onto magnetite in a
programmable and reproducible manner. Up to 100% of the ALN-PEG was coated onto
magnetite as measured by TGA (Figure 14C). We chose magnetite with 20% wt
magnetite and 80% wt polymer for further evaluation due to its outstanding stability and
ability to conjugate sufficient number of ligand molecules.
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To demonstrate the potential of APM as one novel nanomedicine platform for
targeting ligand evaluation and optimization, FA was selected to conjugate to the
ALN-PEG polymer (ALN-PEG-Folate) using amidation strategy (Figure 12Figure 12). For
the preparation of folate-decorated magnetite, OA-coated magnetite was dispersed into
THF, and then ALN-PEG and ALN-PEG-Folate (weight ratio 4:1) were added into this
solution for OA replacement overnight at room temperature. The purification procedures
were same to preparation of APM.

4.4.3. Physicochemical and stability characterization of APM and FAPM
The lyophilized particles are easily dispersed in water and the nanoparticles are very
stable in biological buffers such as PBS. Under an external magnetic field, APM retained
its dispersion stability in PBS while OA-coated magnetite in PBS were colloidally unstable,
precipitated, and were attracted towards a magnetic field within minutes (Figure 14A). To
study the stability of APM, we tested its size and PDI in acidic, basic and high ironic
strength conditions. APM nanoparticles were very stable in various conditions, and there
was no significant increase in size and PDI of APM within the 2 weeks’ timeframe of the
study (Figure 15A). After one month storage on the shelf, APM solutions were clear and
no nanoparticles precipitate out (Figure 15B). The TEM pictures of APM nanoparticles
also confirmed this result (Figure 15C). After two month storage, all APM solutions
remained clear expect APM nanoparticles in NaCl 2M solution precipitated out slightly
(Figure 15B), which was easy to form stable dispersion again with gentle shaking.
The structure of FAPM is illustrated in Figure 13B. The size of APM and FAPM
nanoparticles was assessed by TEM showing that the iron oxide core is morphologically
indistinguishable from each other, with a mean particle size of 10 nm (Figure 14B).
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Concentration dependent relaxivity [r2 (s-1 ml mg-1)] causing increased relaxivity (R2
(s-1)) in tissue as a function of concentration (expressed as mg/ml magnetite) of APM and
FAPM is an important parameter. To investigate the MR signal enhancement effects, the
relaxivity of aqueous magnetite particles at different magnetite concentrations was
determined using a 7T MRI scanner. The magnetite concentrations in mg/ml were plotted
against R2. As shown in Figure 14D, the relaxivity of both APM and FAPM varied linearly
with the magnetite concentration. The relaxivity of FAPM was found to be r2 = 582 (s-1 ml
mg-1) and of APM r2 = 638 (s-1 ml mg-1) (Figure 14D). The r2 values of these particles were
used for noninvasive in vivo quantitation of magnetite concentration using MRI.
CF633-labeled APM and FAPM were synthesized successfully, SPIO coated with
CF633 conjugated ALN-PEG polymer, with CF633 conjugated ALN-PEG and
ALN-PEG-Folate polymer and with oleic acid visualized by UV light (254 nm) exposure
(Figure 16). Only the SPIO with CF633 label showed fluorescence suggesting a
successful dye conjugation.

4.5. Discussion
HIV-1 infected memory effector CD4+ T cells and in more limited numbers, tissue
macrophages, are targets for persistent low-level infection (56, 159). Both are refractory
to immune and chemical elimination and are resistant to virus-associated cytopathicity
(56). HIV-1 has evolved mechanisms to prolong the life span of infected cells (57, 58).
Virus is present for long periods of time in gut, lymphoid and brain reservoirs thus
constituting obstacles for viral eradication within infected individuals (160). One way to
reduce residual virus in its reservoirs is by targeted antiretroviral nanotherapy (136, 149,
161). Nonetheless, adequate targeting schemes have not yet been achieved and current
methods to develop them are commonly slow and cumbersome. To such ends our own
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works have centered on ways to bridge classic PK evaluation with MRI assessment of
particle distributions (158).
FA has emerged as an important targeting moiety capable of specific interaction with
cells expressing the FR. Its expression is restricted to a few cell types, including
mononuclear phagocytes lineage and is regulated by cell activation that is initiated by the
particle itself. Specific drug targeting can thus parallel tissue sites of infection and
consequent

inflammation

along

with

the

reticuloendothelial

system.

MP

and

reticuloendothelial cells would then serve as drug storage depots (136, 137). This,
notably, makes FA conjugation specifically for antiretroviral therapeutic nanoparticles of
particular benefit for treatment of HIV infection (162).
In this study, FA was successfully conjugated to the ALN-PEG polymer, which has
high metal binding affinity. Magnetite with ALN-PEG coating or ALN-PEG and
ALN-PEG-Folate coating showed similar size, shape and relaxivity (Figure 15) which
demonstrates that conjugation of FA doesn’t compromise the stability of the nanoparticle.
Relaxivity of both particles had an excellent regression, and the similar result (582 s-1 ml
mg-1 vs 638 s-1 ml mg-1) is critical to make the magnetite concentration comparable.
APM demonstrated excellent stability in various buffers (Figure 15A, B, C), no
nanoparticles precipitate out after one month storage on the shelf. After 2 months of
storage, all APM dispersions remained stable except APM nanoparticles in the 2 M NaCl
solution where some precipitation was observed which can be reversed with gentle
shaking. The strong binding ability of ALN polymer contribute significantly to the
prolonged shelf life.
We have manufactured a single magnetite particle that is easy to conjugate targeting
ligands, the other potential targeting ligands includes mannose, antibody and peptides.
We posit that the targeting ability of different ligands can be studied further by targeting
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ligand testing of linked magnetic nanoparticles and parallel MRI evaluation of particle
distribution. Moreover, we theorize that such results would closely mimic drug tissue
biodistribution with the same targeting ligands.
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F IGURE 12 ALN-PEG AND ALN-PEG-FOLATE POLYMER SYNTHESIS
(A) Synthesis of ALN-PEG polymer. (B) Synthesis of ALN-PEG-Folate polymer.
(C) 1H NMR spectrum of ALN-PEG polymer.
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F IGURE 13 THE SCHEMATIC STRUCTURE OF APM AND FAPM
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F IGURE 14 APM AND FAPM CHARACTERIZATION
(A) APM and OA coated magnetite under external magnetic field. (B) TEM of APM
and FAPM in PH=7.4 solution. (C) TGA analysis of magnetite with various polymer
coatings. (D) Relaxivity of APM and FAPM.
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F IGURE 15 APM STABILITY
(A) Size and PDI of APM in various conditions for 14 days. (B) APM in various
conditions after one or two month storage. (C) TEM of APM in various conditions after
one month storage.
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F IGURE 16 SPIO COATED WITH DIFFERENT VISUALIZED BY UV LIGHT EXPOSURE
SPIO coated with CF633 conjugated ALN-PEG polymer (left), CF633 conjugated
ALN-PEG and ALN-PEG-Folate polymer (middle) and oleic acid (right) visualized by UV
light (254nm) exposure
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5. Chapter V APM and FAPM
biodistribution analyzed by MRI
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5.1. Abstract
In this proof-of-concept study, biodistribution of APM and FAPM in male Balb/cJ mice
were evaluated. The magnetite concentration was quantified from the change in T 2
weighted relaxivity (R2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite
relaxivity (r2) determined as the slope of magnetite concentration versus R2 in relaxivity
studies.
To this end, we made SMART nanoparticles to rapidly assess ART tissue
biodistribution. SMART testing previously demonstrated near equivalence in drug
biodistribution and PK amongst MRI and drug tissue measurements. Herein, we have
taken this work a step further by demonstrating the utility of FA decoration to facilitate ART
targeting. FAPM improved entry and particle retention to the reticuloendothelial system
over replicate untargeted formulations. The feasibility of imaging APM and FAPM
biodistribution in vivo using MRI was investigated in this chapter. We posit that MRI
testing can predict drug biodistribution, and that the value of targeted magnetite is of
immediate benefit towards the rapid assessment of biodistribution for enhanced drug
tissue concentrations in viral reservoirs in the quest for chemical eradication of HIV
infection.
Our immunohistochemical analysis further demonstrates that APM and FAPM
particles are taken up by liver and spleen macrophages which serve as the reservoir of
these particles, as well as the major targets of HIV.
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5.2. Introduction
Regimen adherence, systemic toxicities and limited drug penetrance to viral reservoirs
are obstacles limiting the effectiveness of long-term antiretroviral therapy. The
development of monocyte-macrophage-targeted nanoART, while providing opportunities
to simplify drug dosing regimens, has proved more limited for its abilities to improve drug
penetrance into viral cell and tissue reservoirs. Research progress was slowed by the
extensive

time

needed

to complete pharmacokinetic,

pharmacodynamics

and

biodistribution testing of nanoART efficacy. We have developed APM and FAPM platform
(158). Their biodistribution would readily be quantitated by a conventional MRI scan to
reflect the targeting ability of the ligand (127, 163).
Our previous studies demonstrated that FR are expressed in differentiated
macrophages, as cell lysates were probed with antibodies to FR1 and FR2 (FRβ) and
showed that FRβ but not FR1 is expressed and localized to the cell membrane.
Engagement of the FR receptor in enhancing FA-coated nanoART uptake was
demonstrated by the ability of free FA to block enhanced FA-nanoART uptake. Our in
vitro studies have demonstrated that the administration of nanoART stimulated the
expression in the FR receptor in macrophages (164).
NanoART with or without the FA targeting ligand were injected into mice to confirm
the usefulness of magnetite to assess ART biodistribution. Such a system can provide a
relevant screening platform and could be used to investigate a broader range of targeting
systems for delivery of nanoART to reservoir sites of viral infection.
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5.3. Experimental Procedures
5.3.1. Manufacture and characterization of FA-P407-ATV/r
Manufacture of nanoATV/r was prepared as described before (165). FA-P407 was
synthesized and used to manufacture FA-nanoATV/r (149). For preparation of FA-P407
ATV and FA-P407-RTV, FA-P407 (0.2% w/v) and P407 (0.3% w/v) were mixed in 10 mm
HEPES to generate micelles; 1% (w/v) drug was added and mixed overnight. For
preparation of P407-ATV and P407-RTV, 0.5% (w/v) P407 was mixed with 1% drug. The
suspensions were homogenized at 20,000 PSI using an Avestin Emulsiflex C3
homogenizer (Avestin Inc, Ottawa, ON, Canada) until the desired particle size (300–400
nm) was reached. Free polymers and non-encapsulated drug particles were removed by
centrifugation; the nanoparticles were resuspended in 0.2% P407. The resulting
nanosuspension was lyophilized and stored in a desiccator protected from light. Drug
loading was determined using reversed phase HPLC and UPLC-MS/MS as described.
Particle size, PDI and zeta potential for the nanoformulations were determined by
dynamic light scattering using a Malvern Zetasizer Nano-ZS instrument (Malvern
Instruments Inc., Westborough, MA, USA).

5.3.2. Biodistribution of APM and FAPM
Biodistribution of APM and FAPM was determined in male Balb/cJ mice (Jackson
Labs, Bar Harbor, ME) after 2 weeks on folate deficient diet (Harlan Teklad TD.00434,
Harlan Laboratories, Indianapolis, IN). Twenty-four hours before administration of
magnetite particles, mice were injected with LPS (Sigma-Aldrich St. Louis, MO) at 2
mg/kg dose intraperitoneally, or injected with 100 mg/kg nanoparticle-based RTV
boosted ATV coated with poloxamer 407 (nanoATV/r), intramuscularly. APM or FAPM (2
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mg iron/kg wt) were injected intravenously in a total volume of 100 µl for each mouse.
The mice were scanned by MRI before and 24 hours after APM or FAPM injection.

5.3.3. MRI acquisition and analyses
MRI was acquired using a 7T/16cm Bruker Pharmascan MRI/MRS scanner (Ettlingen,
Germany) and a commercial mouse body resonator. Magnetite detection by MRI was
done using T2 mapping for quantitation and T2* weighted high resolution imaging for
detection of biodistribution throughout the body. The sequence used for T 2 mapping was
a CPMG phase cycled multislice multiecho sequence. Forty-one 0.5 mm thick contiguous
interleaved coronal images were acquired with an acquisition matrix of 256 x 192, 40 mm
field of view, 12 echoes at 10 ms first echo time and 10 ms echo spacing, repetition time
of 4680 ms, three averages, for a total acquisition time of 30 min. T 2* weighted MRI was
acquired using a 3D spoiled gradient recalled echo sequence with echo time = 3 ms,
repetition time = 10 ms, 15 degree pulse angle, 50 x 40 x 30 mm FOV, 256 x 196 x 128
acquisition matrix, six averages, for a total scan time of 25min.
T2 maps were reconstructed using custom programs written in Interactive Data
Language (IDL; Exelis Visual Information Solutions, McLean, VA). Preinjection and 24
hour postinjection maps were constructed using the even-echo images from the CPMG
phase cycled imaging data set. Mean tissue T2 was determined using ROI analyses
before and after magnetite injection for the 24 hour results. Magnetite concentration was
then determined from the change in relaxivity (ΔR2 = 1/T2preinjection - 1/T2postinjection) and the
per milligram magnetite particle relaxivity (r 2) determined as the slope of magnetite
concentration versus R2 in phantom studies. The ROI analyses were performed using
ImageJ (http://imagej.nih.gov/lj) software.
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5.3.4. PK of FA-nanoATV/r
Male Balb/cJ mice (Jackson Labs), 4-6 weeks old, were maintained on
folate-deficient diet for 2 weeks then injected with 50 mg/kg of nanoATV/r or FA
conjugated nanoATV/r (FA-nanoATV/r). The mice were sacrificed on day 7. Mice with
LPS treatment received LPS (2 mg/kg) 24 hours before receiving drug and were
sacrificed on day 14. The mice were injected with either 50 mg/kg of nanoATV/r or
FA-nanoATV/r. Tissues were collected and stored at -80oC. Tissue drug levels were
determined using UPLC-MS/MS as previously described (166).

5.3.5. Immunofluorescence
Immunofluorescence staining of magnetite particles was determined in male Balb/cJ
mice (Jackson Labs) after 2 weeks on folate deficient diet. Twenty-four hours before
administration of magnetite particles, mice were injected intraperitoneally with LPS at 2
mg/kg, or injected with 100 mg/kg nanoATV/r, intramuscularly. CF633-labeled APM or
CF633-labeled FAPM (2 mg iron/kg wt) was injected intravenously in a total volume of
100 µl for each mouse. After 24 hours, tissues were collected following the MRI scan for
immunofluorescence staining.
Preparations of whole-mount tissues and frozen sections: tissues were collected after
whole mouse perfusion with PBS and fixed in 10% neutral buffered formalin for 24 hours,
then incubated in 15% and 30% sucrose for cryoprotection and embedded in optical
cutting temperature compound (OCT) (Tissue-Tek) at −20 °C. For whole-mount staining,
tissues were cut to 20 µm on a cryostat. Tissues were carefully harvested from melting
OCT.

Immunofluorescence

staining

of

frozen

sections:

sections

were

blocked/permeabilized in Tris Buffered Saline with Tween (TBBS) containing 10% normal
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goat serum, and stained with rabbit monoclonal antibody against Iba-1 (1:500; Wako
Chemicals, USA) and mouse monoclonal antibody against FRβ (a generous gift of Dmitry
Dmitrov, National Cancer Institute, Bethesday, MD) (1:200) for 1 hour at room
temperature. Primary antibodies were labeled with secondary goat anti-mouse for FRβ
antibody and anti-rabbit antibodies for Iba-1 conjugated to the fluorescent probes Alexa
Fluor

488

and

Alexa

Fluor

594,

and

nuclei

were

labeled

with

4′,6-diamidino-2-phenylindole (DAPI). Images were acquired with a Nikon swept field
confocal microscope (Nikon).

5.3.6. Statistical analyses
The data are presented as mean ± SEM. Statistical significance between groups was
assessed using Student’s T-test by Graph-Pad® Prism unless specified. The data were
considered statistically significant if P < 0.05.

5.4. Result
5.4.1. MRI acquisition and analyses
Our previous studies showed that administration of nanoART activated macrophages
and stimulated the overexpression of FR in vivo (149). For the evaluation of the
biodistribution of non-targeted APM and macrophage-targeted FAPM, and their
localization within macrophages in mice, the immune system of mice was first activated
with LPS or nanoATV/r, and then APM or FAPM were administered via intravenous
injection. The APM and FAPM biodistribution were determined by MRI. Figure 17A
displays 0.128 mm thick T2* weighted high-resolution 3D FLASH images of the same
mouse before and 24 hours after injection of APM or FAPM. Presence of magnetite in
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tissue causes a reduction of T2* causing signal loss in proportion to concentration at TE =
3 ms in the liver, spleen, and some abdominal regions.

5.4.2. Biodistribution of APM and FAPM
APM (n=6) and FAPM (n=6) biodistribution in LPS or nanoATV/r treated mice were
quantified from regions of interest in MRI T2 maps (Figure 17B and C). It can be
appreciated that in animals treated with LPS, FAPM showed a higher accumulation in
various tissues compared to APM (2.49 vs 0 µg/ml for renal pelvis, 5.49 vs 0 µg/ml for
renal cortex, 10.94 vs 2 µg/ml for spleen and 26.26 vs 10.48 µg/ml for liver) (Figure 17B)
In animals treated with nanoATV/r, FAPM also showed more accumulation in various
tissues compared to APM (1.02 vs 0 µg/ml for renal pelvis, 0.69 vs 0 µg/ml for renal
cortex, 13.07 vs 5.79 µg/ml for spleen and 17.27 vs 7.53 µg/ml for liver) (Figure 17C).
FAPM accumulated more in various tissues, which demonstrated its targeting ability to
FR on activated tissue macrophages, and showed the potential of APM and FAPM for
assessing image-guided drug PK and BD.
To further confirm this concept, biodistribution of nanoATV/r or FA-nanoATV/r was
evaluated in Balb/cJ mice with or without LPS activation. The mice were injected with
either 50 mg/kg of nanoATV/r or FA-nanoATV/r, and the drug concentrations in different
tissues were quantified by UPLC/MS-MS. The tissue ATV concentrations following
treatment with FA-nanoATV/r were significantly higher than with nanoATV/r and were
found to be dose dependent. A 50 mg/kg FA-nanoATV/r dose gave 1.82 μg/g and 208
ng/g ATV concentrations in liver and spleen, respectively, compared to 439 ng/g and 145
ng/g in liver and spleen following nanoATV/r treatment in LPS-treated mice (Figure 18 A).
Alternately, the ATV tissue concentrations following FA-nanoATV/r were 2.93 μg/g and
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86.3 ng/g compared to 146 ng/g and 2.36 ng/g for nanoATV/r in liver and spleen,
respectively in mice treated only with nanoATV/r (Figure 18 B).

5.4.3. Immunofluorescence
To confirm the in vivo FR-targeting ability of FAPM, the colocalizaiton of magnetite
particle and FR was also studied by administration of CF633-labeled APM and FAPM
(CF633-APM and CF633-FAPM) to mice. Mouse FRβ antibody and Iba-1 antibody were
used to determine colocalization. These were used to detect FR and macrophages.
Results obtained by immunofluorescent staining clearly showed co-localization of FRβ
FRβ and Iba1 in spleen from mice injected with LPS and nanoATV/r, in agreement with
the hypothesis that activated macrophages express FRβ. In addition, CF633-labeled
FAPM were mainly detected in Iba-1+/FR+ cells (Figure 19A and B).

5.5. Discussion
Figure 17A displays 0.128 mm thick T2* weighted high-resolution 3D FLASH images
of the same mouse before and 24 hours after injection of APM or FAPM. Presence of
magnetite in tissue causes a reduction of T 2* causing signal loss in proportion to
concentration at TE = 3 ms in the liver, spleen, and some abdominal regions. The
shortening in the T2* value correlates with the signal intensity decrease as a result of the
strong magnetite susceptibility effects. As a result, tissues containing magnetite appear
darker in post scans demonstrating higher accumulation of FAPM systemically in both
LPS and nanoATV/r pre-treated mice. This method is semi-quantitative, however it does
allow ready identification of the presence of magnetite throughout the body, which can be
used to guide quantitative ROI analyses using T2 maps.
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Prussian blue staining of tissue sections was also performed in liver and spleens of
FAPM treated animals, but showed discordant results. One potential confounding factor
is that the oxidation of magnetite during perfusion and tissue processing could prevent
the success of Prussian blue staining. It is also possible that the ultra small size of the
magnetite results in staining that is undetectable.
In conclusion, we observed parallel patterns of tissue biodistribution between
nanoATV/r or FA-nanoATV/r and APM and FAPM in treated mice. Notably, these
comparable distributions of ATV and magnetite concentrations confirmed the ability of our
ALN-PEG coated magnetite system to be used as a targeting ligand approach to predict
actual drug PK and tissue BD. Future direction includes replacing FA with other
macrophages targeting ligands. Cancer targeting ligands can also be tested in this
platform.
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F IGURE 17 APM AND FAPM BIODISTRIBUTION
(A) 3D gradient recalled echo images of the same mouse before (pre) and 24 hours
after (post) injection of APM or FAPM. APM and FAPM biodistribution in renal pelvis,
renal cortex, spleen and liver, quantified by T2 MRI in (B) LPS or (C) nanoATV/r treated
mice. Data are presented as mean±SEM, *P < 0.05 considered significant using
Student’s t-test.
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F IGURE 18 NANO ATV/ R AND FA- NANO ATV/ R BIODISTRIBUTION IN KIDNEY, SPLEEN
AND LIVER AS QUANTIFIED BY UPLC-MS/MS
These are shown for nanoATV/r in (A) LPS and (B) nanoATV/r treated mice. Data are
presented as mean±SEM, *P < 0.05 considered significant using Student’s t-test. Panel A
and B are days 7 and 14, respectively.
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F IGURE 19 IMMUNOFLUORESCENCE STAINING OF FAPM BIODISTRIBUTION
Immunofluorescence staining of FAPM biodistribution in LPS treated mouse spleen
(top) or nanoATV/r treated mouse spleen (bottom), 200x. (A) phase contrast, (B) DAPI,
(C) IBA-1, (D) folate receptor, (E) magnetite (arrow indicates individual magnetite) and (F)
merge.
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6. Chapter VI Discussion
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There is a considerable focus amongst HIV/AIDS researchers towards the
development of reliable methods to bring drugs to reservoir sites with the explicit goal of
eliminating virus. HIV-1 is present for long periods of time in gut, lymphoid and brain
reservoirs thus constituting obstacles for viral eradication within infected individuals (160).
One way to reduce residual virus in its reservoirs is by targeted antiretroviral nanotherapy
(136, 149, 161). A hurdle towards achieving this goal is the dearth of ways to measure
ART distribution outside of plasma drug levels (118). In addition, adequate targeting
schemes have not yet been achieved and current methods to develop them are
commonly slow and cumbersome. To such ends our own works have centered on ways
to bridge classic PK evaluation with MRI assessment of particle distributions (158).
Taken together, we have developed a polymer system rests in the ability to utilize
MRI scans to rapidly assess cell and tissue drug biodistribution. SMART particles is
polymer-encased dual magnetite and drug particle which is hard to manufacture due to
the different nature of the components. So it is important to find the right composition.
More magnetite will interfere with the incorporation of the ART drug, on the other hand,
less magnetite will cause inefficient MRI signal. After testing different condition for drug
release and relaxivity, we identified that the best drug vs magnetite ratio is 3:1, in which
particles has slow drug release while has adequate magnetite to generate MRI signal. To
increase the biocompatibility of SMART, we used DSPC and DSPE-PEG2k as the shell
of SMART system. To increase drug loading, we used PLGA as the core. To the best of
our knowledge, this is the first attempt to develop lipid-coated PLGA nanoparticles for HIV
therapeutics.
During the first 30 mins of SMART administration, magnetite levels in kidney, spleen
and liver were similar due to the magnetite is still circulating in the blood stream. As
magnetite started to distribute, a higher amount stayed in liver and spleen after 4 hours of
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injection, correlated with higher concentration of magnetite in these organs in 24 hours
MRI scan. Our in vivo MRI results also showed that the concentrations of magnetite and
ATV in mouse tissues, such as liver, spleen and kidney, correlate with one another at 24
h after injection.
The results support the idea that SMART technology could facilitate the noninvasive
evaluation of drug PK and biodistribution in virus target tissues by MRI. Also it
demonstrates the capability of MRI to be used for monitoring ATV distribution by tracking
the presence of magnetite in tissue which causes a reduction of T2*. Targeted drug when
combined with suitable imaging techniques like SMART particles could facilitate this goal
by providing a “go/no go” for treatment success. This technology clearly opens new
opportunities to develop platforms that would accelerate elimination of viral infections.
Another polymer based magnetite system (APM) is also developed for non-invasive
biodistribution study of targeting ligand conjugated nanoparticle. FA is capable of specific
interaction with cells expressing the FR. As FR expression is restricted to a few cell types,
including kidney epithelial cells and mononuclear phagocytes lineage (92) and
expression is regulated by cell activation as present in disease specific targeting of drug
can parallel tissue sites of infection and inflammation along with the reticuloendothelial
system which could then act as a drug storage depot (136, 137). This, notably, makes FA
conjugation specifically for antiretroviral therapeutic nanoparticles of particular benefit for
treatment of HIV infection (162).
We have manufactured a single magnetite particle that is easy to conjugate targeting
ligands with, the other potential targeting ligands includes mannose, antibody and
peptides. We posit that the targeting ability of different ligands can be studied further by
targeting ligand testing of linked magnetic nanoparticles and parallel MRI evaluation of
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particle distribution. Moreover, we theorize that such results would closely mimic drug
tissue biodistribution with the same targeting ligands.
Future direction includes decorating magnetite with other macrophages targeting
ligands or even CD4+ T cells ligands. These potential ligands include HIV gp120-derived
peptides (e.g. CKGIRIGPGRAVYAAE), CCR5-targeting RANTES fragments, hyaluronic
acid, mannose derivatives, and combinations of those ligands.
Targeting ligand with highest accoumlation in viruse reversior found by MRI scanning
will be used to conjugate NanoART particles. Currently NanoART is composed of ATV or
RTV which is not a WHO recommended first line HIV drug. Usage of the first line HIV
treatment for nanoart is promising. NRTIs like 3TC and abacavir, or entry inhibitor
maraviroc are good candidates to incorporate into nanoart to extend drug half-life and
increase bioavailability. NanoART composed of the novel prodrugs and their
combinations can also be prepared using homogenization. Formulations of optimal
physical characteristics will be determined from particle size, charge, PDI and drug
loading capacity to ensure rapid uptake by targeted cells and drug potency. These
nanoART with new drugs can be coated with targeting ligands found by magnetite system
to further facilitate immune responses and promote clearance of virus from cellular
reservoirs. Targeting formulation vs non-targeting formulation uptake by targeted cells
will be tested to evaluate targeting efficiency of the ligand.
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